[
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What are cadherins and catenins, and what roles do they play in breast cancer?\nAnswer: Cadherins and catenins are proteins that are hormonally regulated and play physiological roles during mammary development. However, when deregulated, they can have pathological effects, contributing to breast cancer progression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What is the significance of E-cadherin in invasive lobular breast cancer (ILC)?\nAnswer: E-cadherin expression is irreversibly lost in over 85% of ILC cases, serving as both a tumor suppressor and an invasion suppressor. Its loss is associated with the progression of sporadic breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: How does E-cadherin expression vary in ductal breast cancer compared to lobular breast cancer?\nAnswer: In ductal breast cancer, E-cadherin expression is highly variable and can be reduced due to epigenetic silencing, while in lobular breast cancer, it is often irreversibly lost.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What role do transcriptional regulators play in the modulation of E-cadherin?\nAnswer: Transcriptional regulators such as Snail, SLUG, and ZEB1 bind to the E-cadherin promoter and repress its expression, which is associated with epithelial-to-mesenchymal transitions (EMT) in cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What is the relationship between b-catenin signaling and breast cancer?\nAnswer: b-catenin signaling is upregulated in over 50% of breast tumors and is linked to oncogenic functions related to mammary progenitor cell expansion.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: How do steroid hormones influence cadherin expression in breast cancer?\nAnswer: Steroid hormones, particularly estrogen, have been shown to regulate cadherin expression, maintaining epithelial architecture and potentially influencing tumor behavior.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What is cadherin switching, and how does it relate to breast cancer progression?\nAnswer: Cadherin switching refers to the change in expression from E-cadherin to N-cadherin, which is associated with increased invasion, motility, and metastasis in breast cancer cells.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What are the implications of catenin expression in breast cancer?\nAnswer: Catenins, which connect cadherins to the actin cytoskeleton, are often lost or mislocalized in cadherin-negative breast cancers, and their expression levels can correlate with tumor prognosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What is the role of cancer stem cells (CSCs) in breast cancer?\nAnswer: Some human breast tumors are formed by cancer stem cells expressing CD44, which are capable of self-renewal and generating differentiated progeny, contributing to tumor latency and high rates of remission.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "05f4774599e2489ca24872408194aacf",
            "source": "Adrienne-BreastCancerTreatment-2019",
            "main_category": "Adrienne"
        },
        "page_content": "Question: What future research directions are suggested regarding cadherins and catenins in breast cancer?\nAnswer: Future research should focus on identifying the specific cell types that undergo b-catenin-dependent self-renewal during mammary development and how these processes relate to breast cancer transformation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What is the significance of the intrinsic subtypes of breast cancer?\nAnswer: The intrinsic subtypes of breast cancer, including Luminal A, Luminal B, HER2-enriched, and Basal-like, provide critical insights into the biological heterogeneity of breast cancers, influencing prognosis and treatment response.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What are the characteristics of the Claudin-low intrinsic subtype?\nAnswer: Claudin-low tumors are characterized by low expression of genes involved in tight junctions and cell adhesion, high mesenchymal features, and are often triple-negative, indicating poor prognosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: How do Claudin-low tumors respond to chemotherapy?\nAnswer: Claudin-low tumors show an intermediate response rate to standard neoadjuvant chemotherapy, which is better than Luminal tumors but lower than Basal-like tumors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What role do cancer stem cells (CSCs) play in Claudin-low tumors?\nAnswer: Claudin-low tumors are enriched with cancer stem cell-like properties, which contribute to treatment resistance and tumor initiation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What is the relationship between Claudin-low tumors and BRCA1 mutations?\nAnswer: Claudin-low tumors may arise from BRCA1 mutations, as both metaplastic and medullary carcinomas associated with Claudin-low features show a high incidence of BRCA1 dysfunction.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What are the clinical-pathological features of Claudin-low tumors?\nAnswer: Claudin-low tumors are typically high-grade, often triple-negative, and have a prevalence of 12-14%, with a significant portion being hormone receptor-positive.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: How does the molecular characterization of breast cancer improve treatment strategies?\nAnswer: Molecular characterization allows for better stratification of patients into treatment groups, enhancing the efficacy of therapies tailored to specific breast cancer subtypes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What are the implications of the CSC hypothesis in breast cancer treatment?\nAnswer: The CSC hypothesis suggests that targeting cancer stem cells may improve treatment outcomes, as these cells are often resistant to conventional therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "6d4a0379464c46f0839381cbfc7f4d8b",
            "source": "Aleix-DeconstructurtingTheMolecularPortraintsOfBreastCancer-2010",
            "main_category": "Aleix"
        },
        "page_content": "Question: What future research directions are suggested for understanding Claudin-low tumors?\nAnswer: Future research should focus on the treatment sensitivity of Claudin-low tumors and the identification of effective therapeutic targets, particularly in the context of their stem cell-like characteristics.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What has been the trend in breast cancer incidence in the United States over the past four decades?\nAnswer: Breast cancer incidence has been rising slowly, with an increase of about 0.5% annually from 2010 to 2019.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: How has breast cancer mortality changed since its peak in 1989?\nAnswer: Breast cancer mortality has declined by 43% from 1989 to 2020, equating to approximately 460,000 fewer deaths.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What is the lifetime risk of being diagnosed with invasive breast cancer for U.S. women?\nAnswer: About 1 in 8 U.S. women will be diagnosed with invasive breast cancer during their lifetime.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What are the projected new cases of invasive breast cancer for 2022?\nAnswer: Approximately 287,850 new cases of invasive breast cancer and 51,400 cases of ductal carcinoma in situ (DCIS) are estimated for 2022.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What demographic factors influence the age distribution of breast cancer diagnoses?\nAnswer: The majority of invasive cancers (83%) are diagnosed in women aged 50 years and older, with a median age at diagnosis of 62 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What disparities exist in breast cancer mortality rates among different racial groups?\nAnswer: Black women experience a mortality rate about 40% higher than that of White women, despite a slightly lower incidence rate.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What are the survival rates for breast cancer based on the stage at diagnosis?\nAnswer: Five-year relative survival rates are over 99% for stage I but drop to 29% for stage IV.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: How does screening impact breast cancer outcomes?\nAnswer: Screening, particularly mammography, plays a crucial role in early detection, with prevalence varying by state and significantly lower among uninsured women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What are some contributing factors to the higher mortality rates among Black women with breast cancer?\nAnswer: Factors include later stage at diagnosis, higher prevalence of aggressive tumor subtypes, and disparities in access to quality care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What strategies are suggested to address disparities in breast cancer outcomes?\nAnswer: Strategies include expanding access to high-quality screening and treatment, strengthening community partnerships, and ensuring equitable availability of advanced treatments.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "af7894ace5b54df980ca78382784adc2",
            "source": "Angela-BreastCancerStatistics-2022",
            "main_category": "Angela"
        },
        "page_content": "Question: What percentage of breast cancer cases are linked to modifiable risk factors?\nAnswer: About 30% of breast cancer cases are linked to modifiable risk factors such as excess body weight, physical inactivity, and alcohol intake.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What is the global impact of breast cancer as reported in the document?\nAnswer: Breast cancer is the most common cancer among women worldwide, with approximately 2.3 million new cases and 685,000 deaths reported in 2020.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What percentage of all cancers in Saudi Arabia does breast cancer represent?\nAnswer: Breast cancer represents about 17.7% of all cancers in Saudi Arabia and 31.8% among Saudi females.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What demographic characteristics were analyzed in the study?\nAnswer: The study analyzed demographic variables such as age, nationality, and marital status of breast cancer patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What was the age distribution of breast cancer patients in the study?\nAnswer: The majority of patients (78.1%) were between 40 and 69 years old.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What health condition was most prevalent among the patients?\nAnswer: A significant finding was that 83.0% of the women were classified as overweight or obese.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What tumor characteristics were observed in the study?\nAnswer: Nearly 87% of the tumors were classified as T1 or T2, with invasive ductal carcinoma being the most common histopathological type, accounting for 81% of cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What is the significance of the receptor status findings in the study?\nAnswer: About 70% of the tumors were HER2 negative, 58% were PR positive, and nearly 93% were classified as non-triple negative, which has implications for treatment decisions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What public health implications does the study suggest?\nAnswer: The study underscores the need for enhanced public awareness about the link between obesity and breast cancer, and suggests that screening programs should target women aged 40-69.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What limitations does the study acknowledge?\nAnswer: The study's retrospective design and single-center setting are noted as limitations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "51b4820926a74226b0bebbcf76114375",
            "source": "Banjar-Inc\u0131denceAndClinicopatholigalCharacteristicsOfBreastCancerPatientsFromASingleCenterStudy-2024",
            "main_category": "Banjar"
        },
        "page_content": "Question: What future research directions does the document propose?\nAnswer: Future investigations might focus on longitudinal data to understand the impact of BMI and metabolic health on prognosis and to tailor prevention programs specific to the region's demographics.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What is the main focus of the document?\nAnswer: The document discusses the relationship between pregnancy and breast cancer, including diagnosis, treatment options, and outcomes for women diagnosed with breast cancer during pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the implications of pregnancy on breast cancer prognosis?\nAnswer: Pregnancy-related increases in hormone levels may stimulate the growth of breast cancer, potentially impairing outcomes when the disease is detected during pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What treatment options did the patient in the case report consider?\nAnswer: The patient considered terminating her pregnancy to undergo conventional treatment or continuing with the pregnancy while adjusting her treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What is pregnancy-associated breast cancer?\nAnswer: Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy, lactation, or up to one year postpartum, often presenting with more advanced and aggressive disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the concerns regarding chemotherapy during pregnancy?\nAnswer: Chemotherapy can cross the placenta if given before week 15 of gestation, potentially leading to permanent organ malformations in the fetus.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What does the document say about the timing of chemotherapy in pregnant women?\nAnswer: The document indicates that delaying chemotherapy until the second trimester may not significantly impair outcomes, as one study found no difference in disease-free survival between those treated early and those treated later.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What recommendations are made regarding tamoxifen treatment and future pregnancy?\nAnswer: Patients undergoing tamoxifen treatment are advised to use non-hormonal contraception and to stop tamoxifen for two months before attempting pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What educational resources are mentioned for patients regarding breast cancer and pregnancy?\nAnswer: The document mentions resources such as the US National Cancer Institute, the Royal College of Obstetrics and Gynaecology, and UK charities like Breastcancer.org and Breast Cancer Care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "fdf39da4c3c84323baacc001d8b276db",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What was the outcome of the case report patient after her diagnosis?\nAnswer: After terminating her pregnancy, the patient underwent a wide local excision of the breast cancer, which was confirmed to be a grade 2 invasive ductal carcinoma.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What is the main focus of the systematic review and meta-analysis conducted by B\u00e1lint B\u00e9rczi and colleagues?\nAnswer: The review evaluates the impact of aromatase inhibitors (AIs) on plasma lipid profiles in postmenopausal women with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: How many studies and patients were included in the meta-analysis?\nAnswer: The meta-analysis included 15 studies involving a total of 1708 patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What types of aromatase inhibitors were analyzed in the study?\nAnswer: The study analyzed the effects of anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What were the key findings regarding the impact of LET and EXE on lipid profiles?\nAnswer: LET and EXE led to undesirable changes in lipid profiles, while ANA and TMX showed a more favorable impact.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What lipid parameters were measured in the study?\nAnswer: The study measured serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What significant changes were observed at the 3-month mark for total cholesterol levels?\nAnswer: At 3 months, LET was associated with a significant increase in TC, while EXE led to a significant decrease, and ANA showed a non-significant change.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: Did the study find that the changes in lipid profiles were severe enough to induce dyslipidemia?\nAnswer: The changes may not be severe enough to induce dyslipidemia in patients without pre-existing cardiovascular comorbidities.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What is the clinical significance of the findings from this meta-analysis?\nAnswer: The findings underscore the need for careful monitoring of lipid profiles in patients receiving AIs, especially those with unfavorable baseline lipid status or additional cardiovascular risk factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What limitations were noted in the meta-analysis?\nAnswer: Limitations include heterogeneity among studies, occasional missing data, and variability in laboratory methodologies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "2a1028bc65164502b59a006e9cad8432",
            "source": "Berczi-AromataseLipids-2024",
            "main_category": "Berczi"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future research should explore the long-term cardiovascular outcomes of AI therapy and optimize management strategies for lipid alterations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What is the main objective of the study conducted by Judy Ann Bigby and Michelle D. Holmes?\nAnswer: The main objective was to perform a structured review of the literature to identify areas of greater and lesser knowledge regarding disparities across the breast cancer continuum, from risk and prevention to treatment and mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What methods were used to gather data for the review on breast cancer disparities?\nAnswer: The authors searched OvidMedline and PubMed for published studies from January 1990 to March 2004 that addressed disparities in breast cancer, focusing on articles in English, limited to American populations and women, and describing quantitative outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What significant findings were reported regarding racial disparities in breast cancer?\nAnswer: The review found substantial research on racial disparities in breast cancer screening, diagnosis, treatment, and survival, particularly between black and white women, with gaps in data for other racial or ethnic minority groups.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What are some identified gaps in the research on breast cancer disparities?\nAnswer: Gaps include limited data on disparities related to sexual orientation, language, literacy, and housing, as well as a lack of studies examining prevention, etiology, and access to clinical trials.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: How do socioeconomic factors influence breast cancer disparities?\nAnswer: Socioeconomic factors such as insurance status, educational attainment, and neighborhood characteristics are associated with disparities in treatment and survival outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What is the significance of the 'cancer disparities grid' mentioned in the document?\nAnswer: The 'cancer disparities grid' serves as a visual aid to assess areas of greater or lesser knowledge regarding disparities across the cancer continuum, helping to focus policy, research, and health care interventions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "29efa1609fba4fba8188307fabbced70",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What conclusion do the authors draw regarding the approach needed to address breast cancer disparities?\nAnswer: The authors conclude that a multidisciplinary and multi-pronged approach is necessary to translate existing research into effective interventions to reduce or eliminate breast cancer disparities.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What is the main focus of the study conducted by Blomberg et al.?\nAnswer: The study investigates the role of eosinophils in enhancing the response to immune checkpoint blockade (ICB) in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What challenge does the study address regarding immune checkpoint blockade in breast cancer?\nAnswer: The study addresses the challenge that only a subset of breast cancer patients benefits from immune checkpoint blockade.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What discovery did the authors make about eosinophils in responders to ICB?\nAnswer: The authors found that responders to ICB exhibited increased circulating and intratumoral eosinophils.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: How does ICB affect IL-5 production in CD4\u207a T cells?\nAnswer: ICB stimulates IL-5 production by CD4\u207a T cells, which promotes eosinophil expansion.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What role does IL-33 play in the context of this study?\nAnswer: IL-33 is crucial for recruiting eosinophils into the tumor microenvironment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What was the impact of eosinophils on CD8\u207a T cell activation?\nAnswer: Eosinophils enhance the activation and effector functions of CD8\u207a T cells, which is essential for the antitumor response.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What therapeutic strategy do the authors suggest to improve ICB efficacy?\nAnswer: The authors suggest targeting or engaging the eosinophil axis via IL-5 and IL-33 to boost ICB efficacy in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What methods were used in the study to gather data?\nAnswer: The study used high-dimensional flow cytometry, RNA sequencing, NanoString gene expression analysis, and various in vivo depletion and cytokine-blockade experiments.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What were the clinical findings related to eosinophils in patients treated with anti-PD-1 therapy?\nAnswer: Responders showed a significant increase in circulating eosinophils, which correlated with longer progression-free and overall survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "e94fd1ac75f64919a34c75179399a8a0",
            "source": "Blomberg-IL33CD4-2023",
            "main_category": "Blomberg"
        },
        "page_content": "Question: What conclusion can be drawn from the study regarding the interplay between eosinophils and CD4\u207a T cells?\nAnswer: The study identifies a critical cooperative axis between IL-5-producing CD4\u207a T cells and eosinophils that enhances the antitumor efficacy of ICB in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What are the two main groups of breast cancer risk factors?\nAnswer: The two main groups of breast cancer risk factors are inherent factors (such as age, sex, race, genetic makeup) and extrinsic factors (conditioned by lifestyle, diet, or long-term medical interventions).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the significance of age in breast cancer diagnosis?\nAnswer: Breast cancer is most frequently diagnosed in women around menopause, particularly in those aged 50 and older, with 80% of cases occurring in this age group.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: How does family history affect breast cancer risk?\nAnswer: A history of breast cancer in first-degree relatives significantly increases the risk, with familial cases constituting about 10% of all newly diagnosed breast cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What lifestyle factors can influence breast cancer risk?\nAnswer: Lifestyle factors such as diet, physical activity, and obesity can influence breast cancer risk, with a high-fat diet and lack of exercise being associated with increased incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What role do hormonal factors play in breast cancer risk?\nAnswer: High levels of endogenous estrogens are a well-defined risk factor for breast cancer, particularly in postmenopausal women, and hormonal therapies can also influence risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the impact of breastfeeding on breast cancer risk?\nAnswer: Prolonged breastfeeding is associated with a reduced risk of breast cancer, with each year of breastfeeding estimated to decrease risk by 4.3%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What are the implications of BRCA1 and BRCA2 gene mutations?\nAnswer: Mutations in BRCA1 and BRCA2 genes significantly increase the risk of breast and ovarian cancer, with a 65% risk for BRCA1 and 45% for BRCA2 mutation carriers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: How does the use of oral contraceptives relate to breast cancer risk?\nAnswer: The relationship between oral contraceptive use and breast cancer risk is controversial, with some studies suggesting a slight increase in risk, while others show no significant association.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What dietary habits are linked to breast cancer risk?\nAnswer: Dietary habits that include high-fat foods and processed products can increase breast cancer risk, while diets rich in antioxidants and vitamin D may reduce it.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "b214e74bde514c578c7f1af3766af779",
            "source": "Breast-Cancer-Risk-Factors",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the effect of menopausal hormone therapy on breast cancer risk?\nAnswer: Menopausal hormone therapy, especially with estrogen and progesterone, is associated with an increased risk of breast cancer, particularly with longer duration of use.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What was the main objective of the study conducted on breast cancer patients in Norway?\nAnswer: The main objective was to assess whether breast cancer is curable by analyzing survival data from 14,731 cases reported to the Cancer Registry of Norway.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What model was used to analyze the survival times of breast cancer patients?\nAnswer: The lognormal model was used, which assumes that the logarithms of the survival times are normally distributed.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What was the estimated cured fraction of breast cancer patients according to the study?\nAnswer: The estimated cured fraction was 35% with a standard error.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: How did the cured fraction vary across different stages of breast cancer?\nAnswer: The cured fraction was 54% for Stage 1, 27% for Stage 2, 19% for Stage 3, and 2% for Stage 4.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What was the median survival time for noncured breast cancer patients?\nAnswer: The median survival time for noncured patients was estimated to be 3.6 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What significant observation was made regarding excess mortality in breast cancer patients?\nAnswer: An excess mortality was observed during the entire follow-up period, indicating that breast cancer patients had a higher death rate than the general population.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What factors were found to influence the estimated cure rate in breast cancer patients?\nAnswer: The estimated cure rate was significantly higher in patients younger than 55 years compared to older patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What methodological concerns were raised regarding the estimates for Stages 3 and 4?\nAnswer: The estimates for Stages 3 and 4 should be regarded with caution due to methodological problems and the small number of patients with long follow-up.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What was the follow-up duration for the breast cancer patients in the study?\nAnswer: The follow-up times ranged from 5 to 18 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "adee4e8a4c9748a6bdc8424bfd8b721d",
            "source": "Breast-cancer-survival-competing-risks-and-mixture-cure-model-a-Bayesian-analysis",
            "main_category": "Breast"
        },
        "page_content": "Question: What conclusion did the authors reach regarding the lognormal model's fit to the data?\nAnswer: The lognormal model was found to be a good approximation of breast cancer survival, consistent with late excess mortality and the presence of a cured fraction.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the leading cause of cancer death among women worldwide?\nAnswer: Breast cancer is the leading cause of death from cancer in women worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What are the treatment options for ductal carcinoma in situ (DCIS)?\nAnswer: DCIS is treated with lumpectomy and radiation or with mastectomy. If estrogen receptor-positive, patients may also receive endocrine therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What are the three treatment phases for early invasive and locally advanced breast cancer?\nAnswer: The three treatment phases are preoperative, surgical, and postoperative.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the purpose of preoperative systemic therapy in breast cancer treatment?\nAnswer: The purpose is to decrease the size of resectable breast tumors, render unresectable tumors operable, and allow for sentinel lymph node biopsy instead of axillary lymph node dissection.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the recommended treatment for stage IV (metastatic) breast cancer?\nAnswer: Treatment goals include improving the length and quality of life, using endocrine therapy, chemotherapy, and immunotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What are some risk factors associated with breast cancer?\nAnswer: Risk factors include older age, female sex, early menarche, late menopause, nulliparity, lack of breastfeeding, family history, dense breast tissue, hormone therapy, and a history of radiation therapy to the chest.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the significance of estrogen receptor status in breast cancer treatment?\nAnswer: Estrogen receptor status helps direct treatment, as hormone receptor-positive cancers are amenable to endocrine therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the role of bisphosphonates in breast cancer treatment?\nAnswer: Postmenopausal women receiving postoperative aromatase inhibitor therapy should be offered bisphosphonate therapy to decrease the chance of developing bone metastases and improve survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What is the standard of care for locally recurrent breast cancer initially treated with breast-conserving therapy?\nAnswer: Total mastectomy is the standard of care for locally recurrent breast cancer initially treated with breast-conserving therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "a6aae7ab924340d6a26248638c78daeb",
            "source": "Breast-Cancer-Treatment",
            "main_category": "Breast"
        },
        "page_content": "Question: What are the common treatments for triple-negative breast cancer?\nAnswer: Chemotherapy is the only systemic therapy available for triple-negative breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What is the main focus of Jacques Brisson's article?\nAnswer: The article examines the relationships among family history of breast cancer in first-degree relatives, mammographic features of breast tissue, and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: How many cases and controls were included in the study?\nAnswer: The study included 1,047 cases with newly diagnosed breast cancer and 2,329 controls.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What methods were used to assess family history and mammographic features?\nAnswer: Family history was assessed through interviews, while mammographic features were evaluated by reviewing mammograms for Wolfe's parenchymal pattern and the percentage of breast parenchymal densities.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the relationship between family history and mammographic features?\nAnswer: The study found only a weak relation between family history and mammographic features among controls, indicating that family history did not vary substantially by mammographic parenchymal pattern.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the increase in breast cancer risk associated with family history?\nAnswer: Women with a family history of breast cancer had a 43% increase in risk compared to those without such a history.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: How did mammographic parenchymal patterns relate to breast cancer risk?\nAnswer: Different mammographic parenchymal patterns were associated with varying levels of risk, with P2 and DY patterns linked to higher risk compared to N1 and PI patterns.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What did the study conclude about the joint effects of family history and mammographic features?\nAnswer: The joint effects of family history and mammographic features on breast cancer risk appeared to be additive, suggesting that their roles in breast cancer development are largely independent.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What adjustments were made in the statistical analysis?\nAnswer: Adjustments were made for age and body weight, with a two-variable method used to account for missing weight data.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the impact of adjusting for body weight on the study's findings?\nAnswer: Adjustment for body weight reduced the strength of the relation between family history and mammographic features but increased the strength of the association between mammographic features and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "1899533746c9441aa5f78113bde534e4",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What previous reports did the findings contrast with?\nAnswer: The findings contrasted with previous reports that suggested a greater-than-additive (multiplicative) interaction between family history and mammographic features.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What is the prevalence of breast cancer worldwide?\nAnswer: Breast cancer is the most common cancer among women worldwide and a leading cause of cancer-related death.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: How do breast cancer incidence and mortality rates differ between developed and developing countries?\nAnswer: In developed countries, improved screening and treatment have led to a decline in mortality despite rising incidence, whereas in many developing nations, the disease is often diagnosed at later stages.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What are some endogenous and exogenous risk factors for breast cancer?\nAnswer: Endogenous factors include early menarche, late menopause, nulliparity, late first full-term pregnancy, and genetic mutations like BRCA1/2. Exogenous factors include oral contraceptive use, hormone replacement therapy, diet, alcohol, and obesity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: How does family history affect breast cancer risk?\nAnswer: Family history increases the risk of breast cancer substantially, but overall, only a fraction of cases are due to inherited high-penetrance genes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What is the significance of international variation in breast cancer incidence?\nAnswer: Incidence rates vary considerably by geography, with higher rates in North America and Northern Europe compared to Asia and Africa. Migrant studies show that women moving from low-risk to high-risk regions experience a gradual increase in incidence rates over generations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What are the histological special types of breast cancer?\nAnswer: Up to 25% of breast cancer cases are classified as 'special types' such as tubular, mucinous, medullary, lobular, metaplastic, and adenoid cystic carcinomas, which differ in clinical behavior and prognosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What are the molecular subtypes of breast cancer identified through gene expression profiling?\nAnswer: The molecular subtypes include luminal A, luminal B, HER2-enriched, basal-like, and normal breast-like, which correlate with hormone receptor status, proliferation rates, histological grade, and clinical outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What is the prognosis for luminal A and luminal B tumors?\nAnswer: Luminal A tumors generally have the best prognosis, while luminal B tumors tend to have a worse outcome than luminal A.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What are the implications of understanding the histological and molecular diversity of breast cancer for treatment?\nAnswer: A deeper understanding of this diversity has influenced treatment decisions, leading to the use of targeted therapies and strategies tailored to specific molecular subtypes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What are some modifiable risk factors for breast cancer prevention?\nAnswer: Modifiable risk factors include reproductive history, obesity, alcohol use, and possibly diet.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "6a2cf0509c8a4184ac877eb39e621c07",
            "source": "Britta-HistoricalTypesOfBreastCancerHowSpecialAreThey-2010",
            "main_category": "Britta"
        },
        "page_content": "Question: What is the current understanding of breast cancer as a disease?\nAnswer: Current knowledge emphasizes that breast cancer is not a single disease but a collection of distinct entities with varied epidemiological, histopathological, and molecular features.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What is the main hypothesis presented in the document regarding iodine, selenium, and breast cancer?\nAnswer: The document hypothesizes that iodine and selenium may play a preventive role in the development of breast cancer, particularly in relation to dietary habits in Japan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: How do iodine and selenium relate to breast cancer according to the authors?\nAnswer: Iodine is linked to the production of anti-proliferative compounds and may influence breast tissue proliferation, while selenium is essential for thyroid hormone regulation and works synergistically with iodine.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What dietary source is highlighted as rich in iodine and selenium?\nAnswer: Seaweed is highlighted as a rich dietary source of both iodine and selenium, particularly in Japan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What evidence do the authors provide to support their hypothesis?\nAnswer: The authors reference animal and human studies showing that iodine administration can cause regression of iodine-deficient goiter and benign breast tissue, as well as epidemiological evidence linking dietary iodine and selenium to lower breast cancer incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What are the authors' recommendations for future research?\nAnswer: The authors recommend conducting more rigorous epidemiological studies, including case-control and prospective cohort studies, to better assess the relationship between iodine and selenium status and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What is the significance of Japan's iodine intake in relation to breast cancer incidence?\nAnswer: Japan's high dietary iodine intake, primarily from seaweed, is suggested to be a key factor in the low incidence of both benign and malignant breast conditions observed in Japanese women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What role does selenium play in thyroid hormone regulation?\nAnswer: Selenium is crucial for the proper functioning of mono-deiodinase enzymes that convert thyroid hormones, thus affecting thyroid hormone homeostasis and iodine availability.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "5df47e9749c54cd7a11ef759f3ac2702",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What potential impact does iodine deficiency have on breast tissue?\nAnswer: Iodine deficiency may increase breast tissue sensitivity to estrogen, potentially contributing to the development of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What is the focus of the Phase I/II study conducted by Cescon et al.?\nAnswer: The study focuses on the combination of GSK525762 (molibresib) with fulvestrant in patients with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What are the common adverse events reported in the study?\nAnswer: The most common treatment-related adverse events were nausea (52%), dysgeusia (49%), and fatigue (45%).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What was the objective response rate (ORR) observed in the study?\nAnswer: The objective response rate (ORR) was 13%, which did not meet the prespecified threshold of 25% for advancing to phase II.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What was the significance of circulating tumor DNA (ctDNA) in the study?\nAnswer: In a subgroup analysis, the presence of copy-number amplification in ctDNA was strongly associated with poor progression-free survival (HR, 2.89; P < 0.0001).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What were the dosing levels evaluated in the study?\nAnswer: The study evaluated two dosing levels: molibresib 60 mg plus fulvestrant 500 mg (DL1) and molibresib 80 mg plus fulvestrant 500 mg (DL2).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What were the findings regarding the tolerability of the combination therapy?\nAnswer: The combination of molibresib with fulvestrant demonstrated poor tolerability, with a high incidence of significant adverse events leading to frequent dose modifications.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What was the conclusion drawn from the study regarding the combination therapy?\nAnswer: The combination of molibresib with fulvestrant did not demonstrate clinically meaningful activity, and the therapeutic window for BET inhibitors in this setting may be small.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What was the design of the study?\nAnswer: The study employed a dose-escalation (phase I) and dose-expansion (phase II) design, enrolling patients with relapsed or refractory advanced/metastatic HR+/HER2\u2013 breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: Who funded the study?\nAnswer: The study was funded by GlaxoSmithKline (GSK).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "4dfe6198ca8442118b68d8c653e72b1f",
            "source": "Cescon-Fulvestrant-2024",
            "main_category": "Cescon"
        },
        "page_content": "Question: What is the significance of the study's findings for future research?\nAnswer: The findings raise questions about the efficacy of BET inhibitors in unselected patients and suggest that baseline ctDNA characteristics may help identify prognostic groups.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What is the main focus of the review article by Chaurasia et al.?\nAnswer: The review article focuses on FDA approved drugs and novel formulations for breast cancer therapy, detailing their development, mechanisms of action, clinical applications, and limitations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: Which types of therapies are discussed in the review?\nAnswer: The review discusses cytotoxic agents, hormonal therapies, targeted therapies, nanomedicine approaches, and novel formulations under clinical trial.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What is the significance of Cyclophosphamide in breast cancer treatment?\nAnswer: Cyclophosphamide, first approved in 1959, is significant as it is used in neoadjuvant, adjuvant, and metastatic settings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: How does Doxorubicin Hydrochloride function in breast cancer therapy?\nAnswer: Doxorubicin Hydrochloride is described as a key agent for metastatic breast cancer, with various liposomal formulations enhancing its effectiveness.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What information is provided in Table 1 of the review?\nAnswer: Table 1 provides a comprehensive account of commercial formulations of drugs approved for breast cancer therapy from 1953 to 2023, including drug names, approval years, dosage forms, and manufacturers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What does Table 2 in the review summarize?\nAnswer: Table 2 lists various novel formulations in clinical trials, detailing the drug, type of formulation, condition of breast cancer, clinical trial phase, and supporting references.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What are systemic therapies in the context of breast cancer treatment?\nAnswer: Systemic therapies are drugs used to treat breast cancer that can reach cancer cells throughout the body, administered either orally or via intravenous injection.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What is emphasized about the choice of therapy for breast cancer?\nAnswer: The choice of therapy depends on the type and stage of breast cancer, with combination therapies often used to enhance treatment outcomes and minimize side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What does the review conclude about the progress in breast cancer drug discovery?\nAnswer: The review concludes that despite significant progress, no single drug or combination is entirely free of adverse effects, but advancements have improved survival and quality of life for patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What contributions did the authors make to the article?\nAnswer: The authors contributed through original concept development, literature surveys, drafting, revision, and overall supervision of the article.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "8826b0ce793e49f8b2605fcad1cd3116",
            "source": "Chaurasia-NovelMedicine-2023",
            "main_category": "Chaurasia"
        },
        "page_content": "Question: What financial support did the authors receive for their research?\nAnswer: The authors received financial support from the Uttar Pradesh Council of Science and Technology Lucknow (UPCST) for a research project on formulation development for breast cancer treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What is the global burden of breast cancer according to the review?\nAnswer: Breast cancer is the most common cause of cancer death among women worldwide, with rising incidence and mortality rates, especially in regions that historically had low rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: How does age affect breast cancer incidence?\nAnswer: Incidence increases rapidly during reproductive years and more slowly after age 50, with cumulative incidence rates of approximately 2.7% by age 55, 5.0% by age 65, and 7.7% by age 75 in Europe and North America.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What role do migration studies play in understanding breast cancer risk?\nAnswer: Migration studies show that women moving from low-risk to high-risk regions gradually adopt the higher incidence patterns of their new countries, often reaching native population levels within one or two generations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What are some major reproductive and hormonal risk factors for breast cancer?\nAnswer: Major risk factors include early menarche, childbearing patterns, breastfeeding, age at menopause, and the use of oral contraceptives and hormone replacement therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: How does lifestyle and environmental exposure influence breast cancer risk?\nAnswer: Factors such as alcohol consumption, obesity, physical activity, and exposure to ionising radiation have been linked to increased breast cancer risk, while moderate physical activity appears to be protective.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What genetic factors are associated with breast cancer risk?\nAnswer: A family history of breast cancer and high-risk mutations in genes like BRCA1 and BRCA2 significantly elevate risk, although they account for only about 5% of cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What are the prospects for breast cancer prevention mentioned in the review?\nAnswer: The review emphasizes modifiable lifestyle factors, judicious use of hormonal therapies, and the need for further research into dietary and environmental factors to enhance prevention strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What conclusions does the review draw about hormonal factors in breast cancer epidemiology?\nAnswer: The review concludes that extended exposure to oestrogens is a primary driver of risk, while early childbearing and higher parity are protective factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "022ba635a5284e678acc1314dea4f81c",
            "source": "David-CaseControlStudyOfPhotoOestrogensAndBreastCancer-1997",
            "main_category": "David"
        },
        "page_content": "Question: What lifestyle modifications could help reduce breast cancer incidence?\nAnswer: Efforts to reduce obesity, limit alcohol consumption, and promote physical activity could significantly impact reducing breast cancer incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What is lymphedema and how is it related to breast cancer treatment?\nAnswer: Lymphedema is a condition that arises from damage to or removal of lymph nodes during breast cancer treatment, leading to impaired lymphatic drainage and fluid accumulation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the two main types of lymphedema based on onset?\nAnswer: The two main types of lymphedema are acute lymphedema, which occurs shortly after surgery, and chronic lymphedema, which develops if acute lymphedema is untreated.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the clinical manifestations of acute lymphedema?\nAnswer: Acute lymphedema is characterized by pitting edema, swelling, tightness, and a feeling of heaviness in the affected limb, often resolving within weeks.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What factors increase the risk of developing lymphedema after breast cancer treatment?\nAnswer: Risk factors include surgical procedures like axillary node dissection, radiation therapy, injuries, infections, and lifestyle factors such as air travel.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What preventive measures can be taken to minimize the risk of lymphedema?\nAnswer: Preventive measures include early identification, patient education, avoiding constrictive items, and taking precautions during activities like air travel.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are some management strategies for lymphedema?\nAnswer: Management strategies include Manual Lymph Drainage (MLD), compression therapy, gentle exercises, skin care, and advanced treatments like complete decongestive physiotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What role do nurses play in the management of lymphedema?\nAnswer: Nurses are responsible for early detection, patient education, risk assessment, and advocating for standardized care protocols related to lymphedema.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the implications of lymphedema for breast cancer survivors?\nAnswer: Lymphedema poses a significant challenge for breast cancer survivors, affecting their quality of life and requiring ongoing management and care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What is the significance of regular arm circumference measurement in lymphedema management?\nAnswer: Regular measurement of arm circumference helps in the early detection of lymphedema, with differences of 1\u20131.5 cm serving as a diagnostic indicator.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "3f05b18d911547959234c20336052a55",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What ongoing research is being conducted regarding lymphedema?\nAnswer: Research is focused on less invasive techniques, such as sentinel node biopsy, which may help reduce the risk of lymphedema by preserving lymphatic function.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What is the main motivation behind the study on breast cancer detection?\nAnswer: The study aims to improve early detection of breast cancer through automated analysis of mammograms, addressing challenges such as the volume of images and class imbalance in datasets.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What innovative approach does the study propose for breast cancer detection?\nAnswer: The study proposes a combination of region-of-interest (ROI) extraction and an oversampling technique (SMOTE Tomek Link) to enhance deep learning-based breast cancer detection.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What dataset is utilized in the study for breast cancer detection?\nAnswer: The study uses the RSNA screening mammography breast cancer detection dataset, which contains over 54,000 mammographic images from approximately 11,000 patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: How does the proposed method handle class imbalance in the dataset?\nAnswer: The method employs a hybrid resampling approach using SMOTE to generate synthetic samples for the minority class and Tomek Link removal to clean overlapping or noisy samples.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What are the key steps involved in the ROI extraction process?\nAnswer: The ROI extraction process includes grayscale conversion, thresholding and pixel filtering, object selection and cropping, and resizing the ROIs to a standard dimension.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: Which deep learning models were fine-tuned in the study?\nAnswer: The study fine-tuned several pre-trained CNN architectures, including InceptionV3, InceptionResNetV2, ResNet152V2, DenseNet201, and EfficientNetB7.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What were the experimental results regarding the impact of ROI extraction on model performance?\nAnswer: The study found that applying ROI extraction significantly improved model accuracy, with increases from approximately 55\u201358% to around 82\u201386% for imbalanced data splits.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What was the best performance achieved with the EfficientNetB7 model after applying the oversampling technique?\nAnswer: The EfficientNetB7 model achieved an accuracy of 97.41% after applying the SMOTE Tomek Link oversampling technique.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What advantages does the integration of ROI extraction and SMOTE Tomek Link offer?\nAnswer: The integration enhances focus on critical areas, improves handling of class imbalance, increases computational efficiency, and leads to superior performance in breast cancer detection.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "9fab06bb33c3460da9984c94b365fe58",
            "source": "Defri-RegionOfInterestBasedBreastCancerDetectionWithOversamplingTechnique-2024",
            "main_category": "Defri"
        },
        "page_content": "Question: What future work does the study suggest for improving breast cancer detection methods?\nAnswer: The study encourages further validation on larger, more diverse datasets and the incorporation of additional data augmentation techniques to enhance model robustness.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What factors contribute to the rising incidence of breast cancer worldwide?\nAnswer: Adoption of urbanised lifestyles and changes in reproductive behaviour may partly underlie the continued rise in worldwide incidence of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: How have mammographic screening and systemic therapies impacted breast cancer mortality?\nAnswer: Widespread mammographic screening and effective systemic therapies have led to a stage shift at presentation and reductions in mortality over the past two decades.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What role does loco-regional control play in breast cancer survival?\nAnswer: Loco-regional control of the disease seems to affect long-term survival, and improved surgical margins and radiotherapy techniques could further contribute to mortality gains.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What are the main risk factors for breast cancer?\nAnswer: Age and female sex are major risk factors, with incidence rates rising rapidly between ages 35 and 39, and more than three-quarters of tumours being hormone responsive.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What is the significance of gene-expression profiling in breast cancer treatment?\nAnswer: Gene-expression profiling offers the potential to provide accurate prognostic and predictive information, helping to select the best therapy for individuals and avoid overtreatment or undertreatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What are the differences in breast cancer incidence between racial groups?\nAnswer: Age-standardised incidence rates are higher in white women than in African-American women until about age 50, after which the rates cross, with African-American women having higher rates at younger ages.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What is the impact of hormone-replacement therapy on breast cancer risk?\nAnswer: Hormone-replacement therapy increases the relative risk of breast cancer by roughly 35% after 10 years of use and should be avoided in breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What are the current approaches to breast cancer surgery?\nAnswer: Breast-conservation surgery is now the preferred standard of care for early-stage breast cancer, with a focus on achieving clear surgical margins and minimizing local recurrence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: How does adjuvant systemic therapy improve breast cancer outcomes?\nAnswer: Adjuvant systemic therapies have led to improvements in rates of disease-free and overall survival, particularly when tailored to individual prognostic factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What is the role of neoadjuvant therapy in breast cancer treatment?\nAnswer: Neoadjuvant therapy is used to downstage locally advanced breast cancers, potentially allowing for breast-conservation surgery and providing insights into treatment response.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "902b3c7dd0ea4e6fa93a04e531dac4a9",
            "source": "Early-breast-cancer",
            "main_category": "Early"
        },
        "page_content": "Question: What are the benefits of using selective estrogen receptor modulators for breast cancer prevention?\nAnswer: Selective estrogen receptor modulators like tamoxifen and raloxifene have shown efficacy in reducing the incidence of breast cancer in high-risk women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What is the main focus of the meta-analysis conducted by the Early Breast Cancer Trialists' Collaborative Group?\nAnswer: The meta-analysis investigates whether premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression benefit from aromatase inhibitors compared to tamoxifen.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: How many women were included in the meta-analysis and from how many trials?\nAnswer: The meta-analysis included data from 7030 premenopausal women from four randomised trials.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What were the primary outcomes measured in the study?\nAnswer: The primary outcomes included breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What was the median follow-up period for the study participants?\nAnswer: The median follow-up period was 8.0 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What was the effect of aromatase inhibitors on breast cancer recurrence compared to tamoxifen?\nAnswer: Women allocated to an aromatase inhibitor had a lower rate of breast cancer recurrence compared to those assigned tamoxifen, with a relative risk of 0.79.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What was the absolute reduction in 5-year recurrence risk when using aromatase inhibitors?\nAnswer: The absolute reduction in 5-year recurrence risk was 3.2% (6.9% vs 10.1%).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: Did the study find any significant differences in breast cancer mortality between the two treatment groups?\nAnswer: No significant differences in breast cancer mortality were found between aromatase inhibitors and tamoxifen.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What side effect was more frequent with aromatase inhibitors compared to tamoxifen?\nAnswer: Bone fractures were more frequent with aromatase inhibitors (6.4% vs 5.1%).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What conclusion did the study reach regarding the use of aromatase inhibitors for premenopausal women?\nAnswer: The study concluded that for premenopausal women with early-stage ER-positive breast cancer receiving ovarian suppression, using an aromatase inhibitor instead of tamoxifen reduces the risk of breast cancer recurrence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "2e81089eccfe41b597dec763a7477ce7",
            "source": "EBCTCG-AromataseTamoxifen-2022",
            "main_category": "EBCTCG"
        },
        "page_content": "Question: What is the significance of the findings for future research?\nAnswer: Longer follow-up is needed to determine the long-term impact on mortality and to manage treatment-related side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What is the main focus of the study conducted by Elmore et al.?\nAnswer: The study investigates racial differences in the method of breast cancer detection, the timing of diagnosis and initiation of treatment, and the association of these differences with clinical outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What disparities exist in breast cancer outcomes between black and white women according to the study?\nAnswer: Black women experience later-stage diagnoses, shorter survival times, and higher mortality rates compared to white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What were the methods used to collect data in the study?\nAnswer: Data were collected from medical records, the Connecticut State Tumor Registry, and the U.S. Census, focusing on detection methods, timing measures, and additional variables like demographic characteristics and clinical outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: How did the method of detection differ between black and white women?\nAnswer: Black women were more likely to have their cancer detected after noticing a breast abnormality (61% vs. 33%) and less likely to be diagnosed through screening methods.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What was the median time from first abnormality to diagnosis for black women compared to white women?\nAnswer: The median time for black women was 74 days, while for white women it was 59 days.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What percentage of black women had not initiated treatment within 30 days of diagnosis?\nAnswer: 33% of black women had not initiated treatment within 30 days, compared to 21% of white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What are the implications of the study's findings for clinicians and policymakers?\nAnswer: The findings highlight the need to address barriers to prompt diagnostic evaluation and treatment among black women to reduce racial disparities in breast cancer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d9b3f11555a64be1ab20573daf664b90",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Further studies are needed to explore cultural, systemic, and socioeconomic barriers that contribute to delays in care, and to develop comprehensive interventions to improve equity in cancer care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What is the main focus of the Empowered Wellness document?\nAnswer: The document focuses on navigating breast cancer with strength and knowledge, emphasizing the importance of early detection and awareness of risk factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: How many women in the U.S. are estimated to be diagnosed with breast cancer in 2024?\nAnswer: Approximately 310,720 women in the United States are estimated to be diagnosed with breast cancer in 2024.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What key message does Dr. Zakia Williams-Greene convey regarding breast cancer?\nAnswer: Dr. Zakia Williams-Greene emphasizes that early detection through regular self-breast exams and annual mammograms is crucial for improving treatment success and survival rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What are some risk factors for breast cancer mentioned in the document?\nAnswer: Risk factors include dense breast tissue, a history of benign breast conditions, reproductive factors like early menstruation or late menopause, and genetic predispositions such as BRCA mutations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: Why is genetic testing important for women with a family history of breast cancer?\nAnswer: Genetic testing can guide more aggressive preventive strategies, including enhanced monitoring and considering preventive surgery.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What role do support systems play in the healing journey of breast cancer patients?\nAnswer: A strong support network of family, friends, and healthcare professionals is critical in the healing journey, alongside conventional medical treatments and holistic practices.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What is the accuracy rate of mammograms for early detection of breast cancer?\nAnswer: Mammograms have an approximate accuracy rate of 87%, but there is a 7%\u201312% chance of false positives that may require additional testing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: At what age is it generally recommended to begin mammograms?\nAnswer: It is generally recommended to begin mammograms at age 40 or 45, with the frequency of screening increasing with age.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "5558e3bae988457d9edf3f150ea2d507",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What resources are available for women seeking information on breast health?\nAnswer: Women can visit www.womenofcolor.online for information on breast health, inspiring stories from STEM professionals, and resources tailored for women of color.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What was the main objective of the study on breast cancer metastasisation?\nAnswer: The main objective was to investigate the process of metastasis using primary clinical data and disease events from the Munich Cancer Registry.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: How long was the median follow-up period for the patients in the study?\nAnswer: The median follow-up period was 9.4 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What did the study find about the relationship between primary tumor size and survival following metastases?\nAnswer: The study found that survival following metastases was almost unrelated to primary tumor size.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What was estimated as the time from initiation of metastases to its diagnosis?\nAnswer: The time from initiation of metastases to its diagnosis was estimated to be 5.8 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What role does local recurrence play in the context of metastasisation?\nAnswer: Local recurrence is an indicator of metastases and may also have the potential to metastasise.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What are the implications of the proposed metastases model for clinical practice?\nAnswer: The model underscores the importance of early detection, supports breast-conserving therapy, questions the necessity of axillary dissection, and highlights the limitations of systemic therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What was the sample size of the study and what types of patients were included?\nAnswer: The study included a total of 12,423 patients with invasive breast cancer, excluding those with synchronous or metachronous second non-breast malignancies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What statistical methods were used to analyze the data?\nAnswer: Data were analyzed using the Kaplan\u2013Meier method, log rank chi-square statistic, chi-square tests, and U-tests.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What was the estimated excess mortality due to local recurrence?\nAnswer: Excess mortality due to local recurrence was estimated to be up to 9.3 years after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "ae5be35aaa734afdba42fb29e83b8ad0",
            "source": "Engel-TheProcessOfMetastasistionForBreastCancer-2003",
            "main_category": "Engel"
        },
        "page_content": "Question: What does the study suggest about the timing of metastasis in relation to tumor size?\nAnswer: The study suggests that as tumor size increases, the likelihood of initiating metastasis also increases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What is the main objective of the study conducted by Eyler et al.?\nAnswer: The main objective of the study is to assess three state-level revenue-generating initiatives\u2014income tax check-offs, specialty license plates, and lottery tickets\u2014as methods to raise funds for breast cancer prevention, early detection, research, and education programs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: How many states had income tax check-off programs for breast cancer initiatives?\nAnswer: Eighteen states had programs allowing taxpayers to voluntarily contribute to breast cancer initiatives via income tax forms.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What was the median annual revenue generated from income tax check-offs?\nAnswer: The median annual revenue from these check-offs was approximately $115,000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: How many states offered breast cancer specialty license plates and what was the total revenue generated?\nAnswer: Twenty-six states offered breast cancer specialty license plates, generating over $4.1 million in total revenue.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What was the range of additional fees for specialty license plates?\nAnswer: The additional fees for these plates ranged from $20 to $75, with a mean of $37.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: Which state provided a breast cancer-specific lottery ticket and how much revenue did it raise?\nAnswer: Only Illinois provided a state breast cancer lottery ticket, which raised around $4 million between 2005 and 2009.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What correlation was found between breast cancer mortality rates and the availability of specialty license plates?\nAnswer: States with medium or high breast cancer mortality were about 2.5 times more likely to offer specialty license plates than states with lower mortality rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What factors influence the revenue generated from these initiatives?\nAnswer: The revenue amounts vary based on population differences, the range of available donation mechanisms, and economic conditions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What conclusion did the study reach regarding revenue-generating initiatives for breast cancer?\nAnswer: The study concluded that revenue-generating initiatives can be effective strategies for states to raise funds for breast cancer prevention and early detection, although the success and revenue amounts vary significantly across states.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "368a4c078554447389bb53a4b9ca58e9",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future research should explore the factors influencing revenue variability and assess long-term impacts on breast cancer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What is the main focus of the editorial by Silvia Franceschi?\nAnswer: The editorial examines the relationships between breast size, breast reduction surgery, and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: How might large breast size contribute to breast cancer risk according to the document?\nAnswer: Large breast size may result from increased cell proliferation early in life, leading to a higher number of proliferating ductal stem cells in adulthood, which is central to cancer development.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What factors are believed to promote enhanced cell proliferation in early life?\nAnswer: Elevated estrogen exposure in utero and high energy intake during childhood and adolescence are believed to promote enhanced cell proliferation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What did population studies find regarding breast size and breast cancer incidence among Asian women?\nAnswer: Population studies noted that Asian women, who typically have smaller breasts, tend to have lower breast cancer incidence compared to Western women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What was the outcome of studies using bra cup size as a measure of breast volume in relation to breast cancer risk?\nAnswer: Case-control studies using bra cup size have not consistently supported a strong association with breast cancer risk after adjusting for body mass index.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What did the study by Boice et al. reveal about breast reduction surgery and breast cancer incidence?\nAnswer: The study found that among 7,720 women who underwent breast reduction surgery, only 29 cases of breast cancer were observed versus 53.9 expected, indicating a standardized incidence ratio of 0.5.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What are some methodological challenges mentioned in the document regarding studies on breast cancer risk?\nAnswer: Challenges include calculating the expected number of breast cancers in women with partially removed breast tissue and the influence of subtle alterations in the microenvironment on cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: How is breast reduction surgery conceptualized as a preventive strategy?\nAnswer: Breast reduction surgery is seen as a dual approach that removes excess, potentially cancer-prone tissue and may facilitate the early detection and removal of preneoplastic lesions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What reassurance does the editorial provide to women considering breast reduction surgery?\nAnswer: The findings suggest that breast reduction surgery can contribute to cancer prevention without entirely eliminating the need for regular screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "33329c40cf9148278bff42bd0fd40c2f",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What is the conclusion regarding the relationship between breast reduction surgery and breast cancer risk?\nAnswer: Breast reduction surgery may lower breast cancer risk by removing preneoplastic lesions and reducing overall breast tissue susceptible to malignant transformation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What has been the standard treatment for early breast cancer in the past two decades?\nAnswer: The standard treatment has changed from mastectomy to breast conservation therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: How has screening impacted breast cancer mortality rates?\nAnswer: Screening can achieve up to a 40% reduction in mortality by diagnosing the disease at a biologically earlier stage.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What is the significance of adjuvant endocrine therapy trials?\nAnswer: They have led to prevention trials that show some significant effects in reducing breast cancer incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What are the main factors contributing to breast cancer risk identified in the document?\nAnswer: Factors include hormonal influences, genetic mutations (like BRCA1 and BRCA2), and lifestyle factors such as alcohol consumption.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What role do estrogen receptor (ER) status and tumor grade play in breast cancer prognosis?\nAnswer: High grade ductal carcinoma in situ (DCIS) is likely to develop into poorly differentiated invasive tumors, while low grade DCIS has a reduced likelihood of progression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What is the relationship between alcohol consumption and breast cancer risk?\nAnswer: For every 10 g/day of alcohol intake, there is a 9% increase in the risk of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What are the potential benefits of using selective estrogen receptor modulators like raloxifene?\nAnswer: Raloxifene has led to a significant reduction in ER-positive breast cancers in treated groups compared to controls.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What is the impact of smoking on breast cancer risk according to the document?\nAnswer: Smoking is regarded as neutral in terms of breast cancer risk, although it may lead to a different distribution of tumor types.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What advancements are being made in the surgical treatment of early breast cancer?\nAnswer: There is a trend towards less extensive surgery for smaller tumors, and techniques like sentinel node biopsy are being refined.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "2e84b0f2205b4b558525512e02fb677a",
            "source": "Future-prospects-for-the-prevention-and-cure-of-breast-cancer",
            "main_category": "Future"
        },
        "page_content": "Question: What is the significance of timing surgery in premenopausal women?\nAnswer: Rescheduling surgery to the luteal phase could potentially save 5000 lives annually due to improved survival rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What are the current goals of treatment for metastatic breast cancer (MBC)?\nAnswer: The goals of treatment for MBC are to maintain quality of life and prolong survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the significance of molecular subtypes in the treatment of MBC?\nAnswer: Molecular subtypes of breast cancer, defined by hormone receptor and HER2 status, exhibit different clinical behaviors and responses to treatment, which necessitates tailored treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What are the four molecular subtypes of breast cancer?\nAnswer: The four molecular subtypes are luminal A (HR positive and HER2 negative), luminal B (HR positive and HER2 positive), HER2 (HR negative and HER2 positive), and basal-like (HR negative and HER2 negative).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: How does the presence of circulating tumor cells (CTCs) affect patient prognosis?\nAnswer: Patients with detectable circulating tumor cells have a worse prognosis compared to those without, as CTCs are associated with inferior outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the current stance on the curability of MBC according to clinical guidelines?\nAnswer: Most clinical guidelines consider MBC to be incurable, although there are rare cases of long-term complete remission with targeted therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What advancements in treatment strategies are suggested for MBC?\nAnswer: The document suggests that future treatment strategies should include more effective targeted therapies and individualized management based on molecular subtyping.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the role of cancer stem cells in MBC?\nAnswer: Cancer stem cells may contribute to treatment resistance and highlight potential new targets for therapies aimed at eradicating both stem and non-stem cancer cells.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the importance of early detection of distant metastases in breast cancer?\nAnswer: Early detection of distant metastases may improve clinical outcomes, particularly for patients with high-risk molecular subtypes, although current guidelines do not recommend additional routine imaging.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the hypothesis regarding the movement of cancer cells from primary sites to metastases?\nAnswer: The hypothesis suggests that cancer cells can move directly from primary tumors to metastatic sites or circulate to the bone marrow, where they may remain dormant before spreading.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "477d28e3db0f4f11b783930ae1e95d9b",
            "source": "Future-treatment-strategies",
            "main_category": "Future"
        },
        "page_content": "Question: What is the potential for achieving long-term survival in patients with solitary metastatic lesions?\nAnswer: A small subset of patients with solitary metastatic lesions may achieve complete remission and long-term survival with aggressive and multidisciplinary treatment approaches.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What is the main focus of the study conducted by Gho et al.?\nAnswer: The study investigates the self-reported side effects experienced by breast cancer patients following treatment, examining their incidence, associations with patient characteristics, and the influence of exercise.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What were the primary objectives of the study?\nAnswer: The primary objectives were to quantify the incidence of various side effects reported by breast cancer survivors, explore associations between these side effects and patient characteristics, and determine the influence of current exercise levels on the severity of side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: How many participants were involved in the study and what was their demographic?\nAnswer: The study involved 432 breast cancer patients who were over 18 years old and had a history of breast cancer, recruited from the Breast Cancer Network Australia and Cancer Councils of Victoria and Western Australia.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What method was used to collect data on exercise levels?\nAnswer: Current exercise levels were assessed using the Global Physical Activity Questionnaire Version 2 (GPAQ2), which classified physical activity into 'sufficiently active' versus 'insufficiently active.'",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What were some common side effects reported by participants?\nAnswer: Common side effects included hot flushes, sleep disorders, aching muscles, fatigue, and weight gain.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: How did the type of surgery affect the reported side effects?\nAnswer: Women who had undergone a lumpectomy reported fewer side effects, such as less aching muscle, hot flushes, and weight gain, compared to those who had a mastectomy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What was the relationship between exercise levels and side effects?\nAnswer: Sufficient levels of exercise were associated with a reduced likelihood of experiencing several side effects, including lower odds of weight gain and shoulder limitations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What conclusions did the study reach regarding the impact of exercise on quality of life?\nAnswer: The study concluded that sufficient levels of exercise are consistently associated with a reduced incidence and severity of several side effects, highlighting the potential for exercise-based interventions to improve post-treatment quality of life among breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What implications for practice were suggested for healthcare providers?\nAnswer: Healthcare providers are encouraged to integrate exercise programs into post-treatment care to help mitigate negative side effects experienced by breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "9c4ec39b227948f8bd1390a334ea39a5",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What further research is suggested by the authors?\nAnswer: Further research is needed to explore causal relationships and determine the optimal types and intensities of exercise that yield the most benefit for reducing treatment-related side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What is the main focus of the study conducted by Goddard et al.?\nAnswer: The study examines the real-world uptake and use of HER2 testing among breast cancer patients and its impact on treatment decisions, specifically the use of trastuzumab.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What percentage of breast cancers are associated with HER2 gene amplification?\nAnswer: HER2 gene amplification occurs in approximately 18\u201320% of breast cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What is trastuzumab and why is it significant in breast cancer treatment?\nAnswer: Trastuzumab is an effective drug that targets HER2-positive cancers, and it is significant because it benefits patients with HER2-positive tumors, which are associated with aggressive tumor behavior and poorer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: How did the uptake of HER2 testing change from 1998 to 2000?\nAnswer: The uptake of HER2 testing among patients with invasive breast cancer increased dramatically from 12% in 1998 to over 94% by 2000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What were the testing methods used for HER2 evaluation in the study?\nAnswer: The study primarily used immunohistochemistry (IHC) for HER2 evaluation, with fluorescence in situ hybridization (FISH) used for clarifying equivocal or positive IHC results.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What was the treatment pattern for trastuzumab after 2004?\nAnswer: After 2004, trastuzumab use increased significantly, with 55% of women with invasive breast cancer and HER2 overexpression receiving the treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What does the study conclude about the implementation of HER2 testing in the healthcare system?\nAnswer: The study concludes that HER2 testing is performed systematically on appropriate breast cancer patients, and test results are effectively used to guide trastuzumab treatment decisions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What implications does the study suggest for clinical practice and health systems?\nAnswer: The study suggests that accurate HER2 evaluation is crucial for optimizing treatment decisions, and integrated healthcare systems with robust electronic records can facilitate the effective implementation of advanced diagnostic tests.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "1dddac7e242d40d3931244ced3b45dbc",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What future research directions does the study propose?\nAnswer: The study proposes further research in diverse settings to assess the generalizability of the findings and to explore long-term patient outcomes related to HER2-targeted therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What is the main focus of the editorial from 1954 regarding breast cancer?\nAnswer: The editorial discusses the early exploration of hormone treatments in breast cancer, highlighting the antagonistic biological activities of oestrogens and androgens.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What historical perspective is provided about the relationship between the ovary and the mammary gland?\nAnswer: In 1829, Astley Cooper suggested a functional relationship between the ovary and the mammary gland, leading to the advocacy of oophorectomy as a treatment for breast cancer by 1896.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What were the findings from animal studies regarding hormonal influences on breast cancer?\nAnswer: Animal studies showed that oestrogens and androgens counteract each other, and that castration or removal of ovarian function reduced the incidence of breast cancer in mice.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What clinical applications of hormone treatment were explored in the early days?\nAnswer: Early clinical applications included the use of high doses of testosterone propionate for advanced breast carcinoma, which occasionally resulted in prolonged survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What challenges are highlighted in achieving complete tumor regression with hormone treatments?\nAnswer: The editorial notes that while hormone treatments offered promising avenues, complete and sustained remission was rarely achieved, underscoring the complexity of hormonal influences in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What future directions does the editorial suggest for research in hormone treatment of breast cancer?\nAnswer: The author emphasizes the need for future research to focus on better understanding steroid metabolism and the endocrine environment of breast tissue.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What role do the ovaries play in breast cancer according to the editorial?\nAnswer: The editorial discusses the dual role of the ovaries in promoting and maintaining breast cancer growth through estrogen production, as well as the potential role of androgens.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "177ab218aced4e0790795f92ccbcfaa6",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What was the overall impact of early hormonal treatments on breast cancer patients?\nAnswer: The overall impact of early hormonal treatments was limited, with significant progress made but challenges remaining in achieving complete tumor regression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What is the prevalence and impact of breast cancer worldwide?\nAnswer: Breast cancer is one of the most common cancers in women globally and is the second most common cancer overall, causing about 500,000 deaths annually by the year 2000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What are some intrinsic risk factors for breast cancer that are difficult to modify?\nAnswer: Intrinsic risk factors include age and endogenous hormone levels, which are not easily modified.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: How does family history affect breast cancer risk?\nAnswer: Having a first-degree relative with breast cancer increases the risk by two to three times, especially if the family member was diagnosed before age 40-45.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What role do high-penetrance genes like BRCA1 and BRCA2 play in breast cancer risk?\nAnswer: Mutations in BRCA1 and BRCA2 account for about 10-15% of breast cancer cases and confer a high lifetime risk of up to 85% for BRCA1 carriers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What hormonal influences are associated with an increased risk of breast cancer?\nAnswer: Early menarche, late menopause, nulliparity, and the use of oral contraceptives or hormone replacement therapy can increase breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: How does lifestyle affect breast cancer risk?\nAnswer: Obesity, alcohol consumption, and physical inactivity are lifestyle factors that can increase breast cancer risk, while regular exercise may have a protective effect.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What environmental exposures are linked to breast cancer risk?\nAnswer: High-dose chest irradiation increases risk, while investigations into nonionizing radiation, pesticides, and electromagnetic fields have shown inconsistent results.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What are some prevention strategies for breast cancer?\nAnswer: Prevention strategies include genetic counseling, hormonal interventions, lifestyle modifications, chemoprevention, and early detection through screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What is the importance of screening and early detection in breast cancer?\nAnswer: Mammography and other imaging modalities are crucial for early detection, which is one of the most effective ways to improve breast cancer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "14ab54c880194f86974ee057491d6ecb",
            "source": "Hulka-BreastCancerCauseAndPrevention-1992",
            "main_category": "Hulka"
        },
        "page_content": "Question: What multifaceted approaches are suggested to lower breast cancer incidence?\nAnswer: Combining behavioral modifications, hormonal management, chemoprevention, and early screening is needed to effectively lower breast cancer incidence and mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What percentage of patients with metastatic breast cancer survive more than 5 years?\nAnswer: 5\u201310% of patients with metastatic breast cancer survive more than 5 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What factors are associated with improved survival in patients with metastatic breast cancer?\nAnswer: Factors include being young, having good performance status, adequate body functional reserve, long disease-free interval before recurrence, oligometastatic disease, and low systemic tumor load.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the traditional view of metastatic breast cancer treatment?\nAnswer: Metastatic breast cancer has traditionally been considered incurable with conventional treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the role of a multidisciplinary approach in treating metastatic breast cancer?\nAnswer: An aggressive multidisciplinary approach can result in prolonged disease control by combining local treatment of macroscopic disease and systemic treatment of microscopic disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the definition of 'cure' in the context of metastatic breast cancer?\nAnswer: Traditionally, cancer is considered cured when the disease is totally eliminated and the patient has a normal life expectancy without the threat of recurrence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What are the common sites of metastasis in breast cancer?\nAnswer: The most common sites of metastasis are bone, lung, liver, and brain.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the significance of removing the primary tumor in patients with metastatic breast cancer?\nAnswer: Removing the primary tumor may eliminate it as a source of further metastasis and may improve the effectiveness of subsequent systemic treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What are the systemic treatment options available for metastatic breast cancer?\nAnswer: Systemic treatment options include cytotoxic chemotherapy, antiestrogen therapy, and anti-HER2 therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the current understanding of potentially curative treatment in metastatic breast cancer?\nAnswer: Potentially curative treatment is generally considered for patients with oligometastatic disease and specific favorable characteristics.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "9a0e0c1eaf4f49ceac5257c9490416db",
            "source": "Improvement-of-survival-and-prospect-of-cure-in-patients-with-metastatic-breast-cancer",
            "main_category": "Improvement"
        },
        "page_content": "Question: What is the conclusion regarding the treatment of metastatic breast cancer?\nAnswer: Certain patients may benefit from an aggressive multidisciplinary approach, but whether they are truly 'cured' remains controversial.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: What demographic factors influence breast cancer incidence?\nAnswer: Breast cancer incidence increases with age, particularly steeply until age 50, and then slows after menopause. Higher incidence rates are also observed in women from higher socioeconomic classes, those who are never married, and those living in urban or Northern U.S. areas.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: How do reproductive factors affect breast cancer risk?\nAnswer: Earlier menarche and later menopause increase lifetime exposure to estrogens, raising risk. Women who have their first full-term pregnancy later in life also have a higher risk, while higher parity tends to lower risk, especially with early pregnancies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: What role does family history play in breast cancer risk?\nAnswer: A positive family history, particularly involving premenopausal or bilateral breast cancer in a first-degree relative, is a significant risk factor. However, known risk factors account for only about 25% of breast cancer cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: What types of benign breast disease are associated with increased breast cancer risk?\nAnswer: Women with certain benign breast conditions, especially those with proliferative disease or atypical hyperplasia, are at increased risk for developing breast cancer later.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: How does radiation exposure relate to breast cancer risk?\nAnswer: High doses of ionizing radiation, particularly from therapeutic exposures, increase breast cancer risk, with greater risk associated with exposure at younger ages.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: What ongoing research areas are being explored in breast cancer epidemiology?\nAnswer: Research is focused on refining measurements of exposures, determining critical periods for exposure effects, and investigating unexplained risk factors that may contribute to breast cancer incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "97e2efc7902648a78308fa7bc124143b",
            "source": "Jennifer-BreastCancerEpidemiology-1988",
            "main_category": "Jennifer"
        },
        "page_content": "Question: What is the conclusion regarding the understanding of breast cancer risk factors?\nAnswer: While established risk factors include age, reproductive history, family history, benign breast disease, and certain exogenous exposures, much of the overall risk remains unexplained, highlighting the need for further research.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the leading cause of cancer death among women worldwide?\nAnswer: Breast cancer is the leading cause of death from cancer in women worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What are the treatment options for ductal carcinoma in situ (DCIS)?\nAnswer: DCIS is treated with lumpectomy and radiation or with mastectomy. If estrogen receptor-positive, patients may also receive endocrine therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What are the three treatment phases for early invasive and locally advanced breast cancer?\nAnswer: The three treatment phases are preoperative, surgical, and postoperative.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the purpose of preoperative systemic therapy in breast cancer treatment?\nAnswer: The purpose is to decrease the size of resectable breast tumors, render unresectable tumors operable, and allow for sentinel lymph node biopsy instead of axillary lymph node dissection.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the recommended treatment for stage IV (metastatic) breast cancer?\nAnswer: Stage IV breast cancer is treatable but not curable, with treatment goals focused on improving length and quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What are some risk factors associated with breast cancer?\nAnswer: Risk factors include older age, female sex, early menarche, late menopause, nulliparity, lack of breastfeeding, family history, dense breast tissue, hormone therapy, and a history of radiation therapy to the chest.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the role of genetic assessment in breast cancer risk?\nAnswer: Validated risk assessment tools can identify women at risk of BRCA1/2 gene mutations and guide screening and genetic counseling.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the standard treatment for hormone receptor-positive breast cancer?\nAnswer: Hormone receptor-positive breast cancer should be treated with endocrine therapy, which may include tamoxifen or aromatase inhibitors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the significance of sentinel lymph node biopsy in breast cancer treatment?\nAnswer: Sentinel lymph node biopsy is preferred over axillary lymph node dissection for patients without clinical evidence of nodal disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What are the common systemic breast cancer drugs and their adverse effects?\nAnswer: Common systemic drugs include bisphosphonates, chemotherapy agents like doxorubicin and paclitaxel, and endocrine therapies like tamoxifen, each with specific adverse effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "0f489819577d45b1a84b74492690091d",
            "source": "Kathryn-BreastCancerTreatment-2021",
            "main_category": "Kathryn"
        },
        "page_content": "Question: What is the recommended approach for recurrent breast cancer treatment?\nAnswer: The treatment of recurrent breast cancer requires a multidisciplinary approach, considering all potential options for optimal outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What is the main focus of the study on breast cancer metastasis?\nAnswer: The study analyzes the relationship between metastasis, local recurrence, and survival in relation to primary tumor characteristics in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What significant finding does the study reveal about the timing of metastasis?\nAnswer: The study finds that metastases may begin well before the primary tumor is diagnosed.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: How does tumor size affect the frequency of metastasis according to the study?\nAnswer: The frequency of metastasis significantly increases with tumor size, from 1.1% in the smallest tumors (pT1) to 21.1% in the largest (pT4).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What role does local recurrence play in breast cancer metastasis?\nAnswer: Local recurrence is highlighted as an important indicator of metastasis and is correlated with reduced survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What does the study suggest about the relationship between local recurrence and secondary metastasis?\nAnswer: The study raises the question of whether local recurrence can lead to secondary metastasis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What implications does the study have for clinical practice regarding lymph node dissection?\nAnswer: The findings suggest that extensive lymph node dissection and irradiation might be reduced without compromising outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What is the estimated time from metastasis initiation to diagnosis as per the study?\nAnswer: The estimated time from metastasis initiation to diagnosis is around 5.8 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What does the study conclude about the systemic nature of breast cancer at diagnosis?\nAnswer: The authors conclude that breast cancer is likely systemic at the time of diagnosis for many patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What is emphasized as crucial for improving outcomes in breast cancer treatment?\nAnswer: Early detection and optimal local therapy are emphasized as crucial for improving outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "3fb28229eaae461893a304e8d7a304d5",
            "source": "Kornelia-BreastCancerOriginsAndEvolution-2007",
            "main_category": "Kornelia"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: The study suggests that a better understanding of the timing and process of metastasis could guide the development of more effective treatment strategies and screening protocols.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What is the main focus of the report by Kotsopoulos and Narod?\nAnswer: The report explores the potential for dietary modification to reduce the risk of hereditary breast cancer in women carrying deleterious mutations in the BRCA1 or BRCA2 genes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What is the estimated lifetime risk of breast cancer for BRCA1 and BRCA2 mutation carriers?\nAnswer: The lifetime risk of breast cancer for BRCA1 and BRCA2 mutation carriers is estimated to be between 38% and 87%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: How do environmental and lifestyle factors influence cancer risk among BRCA mutation carriers?\nAnswer: Variability in cancer risk among carriers suggests that environmental and lifestyle factors, including diet, may modify cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What role does estrogen play in BRCA-associated carcinogenesis?\nAnswer: Estrogen-induced cell proliferation and DNA damage are central to breast carcinogenesis, and BRCA gene products are involved in DNA damage repair pathways.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What dietary components are proposed as potential chemopreventive agents?\nAnswer: Nutrients and phytochemicals such as diindolylmethane (DIM), indole-3-carbinol (I3C), lycopene, selenium, and green tea polyphenols are highlighted as candidate agents.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What are the proposed mechanisms by which dietary agents may reduce breast cancer risk?\nAnswer: Dietary agents may decrease oxidative DNA damage, enhance DNA repair capacity, and favorably modulate estrogen metabolism.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What challenges do researchers face in conducting prospective trials for dietary interventions in high-risk populations?\nAnswer: Prospective trials with breast cancer as an endpoint are challenging in high-risk populations, necessitating the identification and validation of intermediate biomarkers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What is the conclusion of Kotsopoulos and Narod regarding dietary intervention?\nAnswer: They conclude that while the evidence is preliminary, dietary intervention holds promise as a complementary strategy for the prevention of hereditary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "be4d520d157d48a990a51ea402e46327",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What further research do the authors call for?\nAnswer: The authors call for research to identify and validate reliable biomarkers of DNA damage and repair, conduct well-designed studies distinguishing between carriers and non-carriers, and evaluate the effectiveness of specific dietary regimens or supplements.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What is the global burden of breast cancer?\nAnswer: Breast cancer is the most common cancer among women worldwide and a leading cause of cancer-related deaths, with higher incidence in developed countries.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: How does breast cancer incidence vary with age?\nAnswer: Incidence increases steadily with age, rapidly during the premenopausal years (ages 40\u201355) and at a slower rate after menopause.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What geographical variations exist in breast cancer incidence?\nAnswer: Industrialized regions report higher rates (60\u2013100 cases per 100,000 women) compared to parts of Asia and Africa, which report less than 40 cases per 100,000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What hormonal factors influence breast cancer risk?\nAnswer: Early menarche, late menopause, older age at first full-term pregnancy, and nulliparity increase risk, while early full-term pregnancy and prolonged lactation are protective.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: How do genetic factors affect breast cancer risk?\nAnswer: Having first-degree relatives with breast cancer increases risk two to threefold, and high-penetrance gene mutations like BRCA1 and BRCA2 significantly elevate lifetime risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What lifestyle factors are associated with breast cancer risk?\nAnswer: Obesity, high dietary fat intake, and moderate-to-heavy alcohol consumption are linked to increased risk, while physical activity may reduce risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What are the recommended methods for early detection of breast cancer?\nAnswer: Mammography is the gold standard for early detection, with supplemental imaging for high-risk women. Self-examination and clinical examination can promote earlier recognition of changes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What lifestyle modifications can help reduce breast cancer risk?\nAnswer: Encouraging weight control, reducing alcohol intake, and increasing physical activity can lower risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What pharmacologic and surgical interventions are available for high-risk women?\nAnswer: Tamoxifen and aromatase inhibitors can be used for risk reduction, and prophylactic surgeries may be considered for women with a strong family history or known BRCA mutations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "7dd5b0acb1da405486e337f01fdaf989",
            "source": "Lipwoth-EpidemiologyOfBreastCancer-1995",
            "main_category": "Lipwoth"
        },
        "page_content": "Question: What is the importance of public awareness in breast cancer prevention?\nAnswer: Ongoing education is essential to improve knowledge about breast cancer signs, risk factors, and the importance of regular screening, especially in resource-limited regions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What is the main objective of the study on personal control in women with breast cancer?\nAnswer: The study aims to examine the moderating effect of disappointing news on the adaptiveness of personal control over cure in women with breast cancer and to explore the underlying beliefs and correlates of control over cure.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: How was data collected for the study?\nAnswer: Data were collected through questionnaires and face-to-face interviews with women who were newly diagnosed with breast cancer, both before surgery and after treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What were the key findings regarding chemotherapy prescriptions and personal control?\nAnswer: The study found that a chemotherapy prescription neither enhances nor limits the adaptiveness of disease-specific or general control perceptions in women with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What beliefs did women with a strong sense of control over cure report?\nAnswer: Women reported that maintaining a positive attitude, accepting treatment, and adopting a healthy lifestyle gave them a sense of control over their cure.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What demographic factors were associated with a strong sense of control over cure?\nAnswer: Women with a strong sense of control over cure were often younger, had invasive cancer, and were characterized by high optimism and a strong sense of control over life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What does cognitive adaptation theory suggest about personal control?\nAnswer: Cognitive adaptation theory suggests that personal control acts as a stress buffer when facing adversity, helping individuals maintain an optimistic outlook and prevent feelings of helplessness.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What were the hypotheses regarding the effect of disappointing news on personal control?\nAnswer: The hypotheses were that disappointing news after surgery might either enhance the adaptiveness of personal control over cure or reduce it due to disconfirmation of control beliefs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What were the results regarding the relationship between personal control and psychological outcomes?\nAnswer: The study found that personal control over cure did not have a main effect on psychological outcomes, but personal control over life predicted less anxiety and threat appraisal after treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What limitations were noted in the study?\nAnswer: Limitations included a small final sample size, potential bias due to incomplete assessments before surgery, and the inability to generalize findings to patients with terminal cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "c51d8e92790c486f90151fdf36f4b81b",
            "source": "Major-patterns-of-cancer-cure-Clinical-implications",
            "main_category": "Major"
        },
        "page_content": "Question: What implications do the findings have for clinical practice?\nAnswer: The findings suggest that strong cancer-specific control perceptions in newly diagnosed patients treated with curative intent may not need to be altered, as they could reflect an adaptive capacity to cope with cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What is triple-negative breast cancer (TNBC)?\nAnswer: TNBC is a subtype of breast cancer that lacks estrogen, progesterone, and HER2 receptors, accounting for approximately 15\u201320% of breast cancer cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What are the traditional chemotherapeutic agents used for TNBC?\nAnswer: Traditional chemotherapeutic agents for TNBC include taxanes (such as paclitaxel and docetaxel) and anthracyclines (such as doxorubicin and epirubicin).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: Which FDA-approved therapies are available for TNBC?\nAnswer: FDA-approved therapies for TNBC include paclitaxel, docetaxel, doxorubicin, epirubicin, PARP inhibitors like olaparib and atezolizumab, and the immunotherapeutic agent Keytruda.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What is the significance of PARP inhibitors in TNBC treatment?\nAnswer: PARP inhibitors, such as olaparib, are approved in combination with chemotherapy to enhance efficacy and reduce adverse outcomes in TNBC treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What recent advancements have been made in TNBC treatment?\nAnswer: Recent advancements include the approval of targeted therapies like Trodelvy, olaparib, and Keytruda, reflecting a better understanding of the signaling pathways driving TNBC.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What are the molecular subtypes of TNBC?\nAnswer: The molecular subtypes of TNBC include basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) subtypes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What is the impact of TNBC on patient outcomes?\nAnswer: TNBC is associated with aggressive behavior, higher recurrence rates, and poorer outcomes compared to other breast cancer subtypes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "86380ae1be154fa4b772655edec5ccd9",
            "source": "MandapatiLukong-TNBC-2023",
            "main_category": "MandapatiLukong"
        },
        "page_content": "Question: What is the purpose of the review article by Mandapati and Lukong?\nAnswer: The review article outlines current FDA-approved treatments for TNBC and elucidates their mechanisms of action, including conventional chemotherapies and targeted therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What was the age and condition of the patient presented in the case overview?\nAnswer: The patient was a 47-year-old premenopausal woman with a 1.2 cm palpable breast mass.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What significant family history did the patient have?\nAnswer: The patient's family history included a paternal aunt with postmenopausal estrogen receptor-positive breast cancer and a paternal grandmother with ovarian cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What type of breast cancer was confirmed by the core needle biopsy?\nAnswer: The biopsy confirmed a moderately differentiated infiltrating ductal carcinoma.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What were the immunohistochemistry results for the patient's tumor?\nAnswer: The tumor was strongly positive for estrogen receptors (99%), moderately positive for progesterone receptors (55%), and negative for HER2 (11%).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What genetic variant was identified in the patient?\nAnswer: A pathogenic variant in the ATM gene (c.538C>T) was identified, leading to a premature stop codon.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What challenges are associated with expanded genetic testing for breast cancer?\nAnswer: Expanded genetic testing has revealed that many women carry mutations in moderate-risk genes, which complicates risk assessment and management due to their lower penetrance and unclear family history patterns.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: How should women with breast cancer who carry moderate-risk variants be managed?\nAnswer: They should generally be managed similarly to those without such mutations, as seen in the case where the patient was offered breast-conserving surgery.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What is the recommended approach for surveillance in women with moderate-risk gene variants?\nAnswer: Enhanced screening measures, such as starting MRI screening at age 40, are usually advised for those found to carry moderate-risk variants.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What was the final pathology stage of the patient after surgery?\nAnswer: The final pathology stage was pT1cN0M0.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What treatment did the patient elect to receive post-surgery?\nAnswer: The patient elected to receive adjuvant antiestrogen treatment along with radiotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "2113025a8a86437bab88c549e888704b",
            "source": "Mark-ManagementOfWomanWithBreastCancerAndPathogenicVariantsInGenesOtherThan-2021",
            "main_category": "Mark"
        },
        "page_content": "Question: What is the clinical take-home message from the presentation?\nAnswer: Management of breast cancer in women with pathogenic variants in moderate penetrance genes should be tailored based on the individual's overall risk profile, emphasizing personalized counseling and appropriate surveillance.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What is the primary focus of the document?\nAnswer: The document focuses on the epidemiology, risk factors, and genetic determinants of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What percentage of all female cancers worldwide does breast cancer account for?\nAnswer: Breast cancer accounts for approximately 18% of all female cancers worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: How does the incidence of breast cancer vary geographically?\nAnswer: Incidence and mortality rates can vary up to fivefold between countries, indicating the influence of environmental factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What are some key reproductive factors that increase breast cancer risk?\nAnswer: Key reproductive factors include early menarche, late menopause, nulliparity, and late age at first full-term pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What role do genetic factors play in breast cancer risk?\nAnswer: Genetic factors, particularly mutations in high-penetrance genes like BRCA1 and BRCA2, account for a substantial portion of hereditary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What lifestyle factors are implicated in increasing breast cancer risk?\nAnswer: Obesity in postmenopausal women, high dietary fat intake, and alcohol consumption are lifestyle factors that increase breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What is the significance of early detection in breast cancer?\nAnswer: Early detection through screening, such as mammography, is crucial as it can reduce mortality, although it has little impact on incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "44a4a37007b341369539e9efe0bcf2d0",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What conclusion does the review draw about breast cancer?\nAnswer: The review concludes that breast cancer is a multifactorial disease influenced by genetic, hormonal, reproductive, and lifestyle factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What is the main objective of the systematic review conducted by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG)?\nAnswer: The main objective is to provide an updated meta-analysis of randomized trials comparing adjuvant tamoxifen for any duration versus no tamoxifen treatment for women with early breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: How many women and trials were included in the EBCTCG's updated overview?\nAnswer: The overview included data from 37,000 women across 55 trials that began before 1990.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What were the proportional reductions in recurrence rates for women receiving 1 year, 2 years, and approximately 5 years of adjuvant tamoxifen?\nAnswer: The proportional reductions in recurrence rates were 21% for 1 year, 29% for 2 years, and 47% for approximately 5 years of treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What was the observed trend regarding the effect of tamoxifen treatment duration on mortality rates?\nAnswer: A significant trend was observed with greater effects on mortality rates with longer treatment duration, showing reductions of 12% for 1 year, 17% for 2 years, and 26% for approximately 5 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What were the absolute improvements in 10-year survival for node-positive and node-negative women receiving about 5 years of tamoxifen?\nAnswer: For node-positive women, there was a 10.9% improvement (61.4% vs 50.5% survival), and for node-negative women, a 5.6% improvement (78.9% vs 73.3% survival).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What was the effect of tamoxifen on contralateral breast cancer incidence?\nAnswer: The proportional reductions in contralateral breast cancer were 13% for 1-year, 26% for 2 years, and 47% for approximately 5 years of tamoxifen treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What was the impact of tamoxifen on the incidence of endometrial cancer?\nAnswer: The incidence of endometrial cancer was approximately doubled in the 1 or 2-year tamoxifen trials and quadrupled in the 5-year trials.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "6f46b2efbb3141ad81eeef5d6848f78e",
            "source": "Mike-TamoxifenForEarlyBreastCancer-2001",
            "main_category": "Mike"
        },
        "page_content": "Question: What conclusion did the authors reach regarding the use of tamoxifen for women with ER-positive tumours?\nAnswer: The authors concluded that treatment with tamoxifen substantially improves 10-year survival for women with ER-positive tumours and for those with unknown ER status.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What is the main focus of the document?\nAnswer: The document focuses on a community health worker intervention aimed at educating and navigating low-income Latina women towards receiving appropriate cancer screening tests for breast, cervical, and colorectal cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What percentage of all U.S. cancers do breast, cervical, and colorectal cancers account for?\nAnswer: These cancers account for 24% of all U.S. cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What is the significance of early detection through screening?\nAnswer: Early detection through screening significantly improves survival rates, yet screening rates among Latinas remain below national goals.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What theoretical framework was used for the intervention?\nAnswer: The intervention was based on the Health Belief Model (HBM), which includes factors such as perceived susceptibility, severity, benefits, barriers, cues to action, and self-efficacy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: How were community health workers (CHWs) trained for the intervention?\nAnswer: CHWs were trained intensively over a 2-week period, with booster sessions and ongoing monthly meetings, covering study protocols, cancer risk factors, screening guidelines, and navigation support strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What types of educational sessions were conducted?\nAnswer: Educational sessions were conducted in small classroom settings using bilingual flip charts to explain anatomy, risk factors, and recommended screening tests, lasting about 90 minutes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What was the demographic profile of the participants?\nAnswer: The mean age of participants was 46 years, with approximately 53% being U.S.-born, many from lower socioeconomic backgrounds, and a significant proportion being uninsured and primarily Spanish-speaking.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What were the results regarding knowledge gains after the intervention?\nAnswer: Significant improvements in knowledge were observed, such as an increase in correct knowledge of mammogram starting age from 4.3% to 9.9%, and colorectal cancer screening knowledge from 19% to 70%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What was the impact of the intervention on screening behavior?\nAnswer: Overall, 25% of eligible participants reported receiving at least one screening test after the intervention, and those who attended educational sessions were significantly more likely to report receipt of a screening test.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "470d0481224d45bababbe569ea3b0012",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What are the implications for public health practice based on the study's findings?\nAnswer: The study highlights the potential of community-based interventions to enhance cancer prevention efforts in underserved populations and supports the integration of CHWs in preventive health programs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: What are CDK4/6 inhibitors and their role in breast cancer treatment?\nAnswer: CDK4/6 inhibitors are drugs that, when combined with endocrine therapy, have become the standard-of-care for patients with advanced hormone receptor-positive, HER2 non-amplified breast cancer, and are also used in high-risk early stage disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: What challenges are associated with the use of CDK4/6 inhibitors?\nAnswer: Challenges include acquired resistance, patient selection, optimal treatment timing, and sequencing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: What does the review outline regarding CDK4/6 inhibitors?\nAnswer: The review outlines the biological rationale for targeting CDK4/6, summarizes recent clinical evidence, compares approved inhibitors, and discusses future research directions to overcome resistance and refine treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: What are the key sections covered in the review?\nAnswer: Key sections include CDK4/6 and the cell cycle, CDK4/6 in breast cancer, the role of CDK4/6 inhibitors in antitumor immunity, comparisons among clinically approved inhibitors, biomarker analysis, mechanisms of acquired resistance, and future directions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: Who are the authors of the review article?\nAnswer: The authors are Laura Morrison, Sibylle Loibl, and Nicholas C. Turner.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "18b0dc1f49f44e008019fc03fa9cda50",
            "source": "MorrisonLoiblTurner-CDK46Rev-2024",
            "main_category": "MorrisonLoiblTurner"
        },
        "page_content": "Question: Where can the full article be accessed?\nAnswer: The full article can be accessed online at https://doi.org/10.1038/s41571-023-00840-4.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the primary goal of evolving breast cancer treatment strategies?\nAnswer: The primary goal remains improved survival, with an increasing emphasis on reducing treatment morbidity and enhancing quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: How effective is prophylactic mastectomy in reducing breast cancer risk for high-risk women?\nAnswer: Prophylactic mastectomy has been shown to reduce breast cancer risk by approximately 90% in high-risk women, including those with BRCA1 and BRCA2 mutations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What are some strategies to lower breast cancer risk in high-risk populations?\nAnswer: Strategies include performing oophorectomy, using tamoxifen, and undergoing prophylactic mastectomy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is sentinel node biopsy and its significance in breast cancer treatment?\nAnswer: Sentinel node biopsy is a less invasive technique for axillary staging with high identification rates (over 90%) and a false-negative rate of less than 5%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What role do BRCA1 and BRCA2 mutations play in breast cancer risk?\nAnswer: Approximately 10% of breast cancers are due to BRCA1 or BRCA2 mutations, with lifetime risks ranging from 55% to 85% by age 70.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What did the NSABP P-1 prevention trial demonstrate regarding tamoxifen?\nAnswer: The NSABP P-1 prevention trial demonstrated that tamoxifen reduces the incidence of breast cancer by about 49% in women at high risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What are aromatase inhibitors and their role in breast cancer treatment?\nAnswer: Aromatase inhibitors, such as anastrozole and letrozole, are effective first-line treatments for hormone receptor\u2013positive metastatic breast cancer in postmenopausal women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the mechanism of action of fulvestrant in breast cancer treatment?\nAnswer: Fulvestrant binds to the estrogen receptor, leading to its degradation, and early studies suggest its antitumor activity is comparable to that of anastrozole.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the focus of ongoing research in breast cancer treatment?\nAnswer: Ongoing research focuses on risk reduction, chemoprevention strategies, and improved surveillance protocols for high-risk populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "f71eed036365462b93d9442577df1ff2",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What funding supported the research discussed in the document?\nAnswer: The work was supported by grants from specialized research programs in breast cancer and foundations, with no competing interests declared by the authors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What are the main subtypes of breast cancer?\nAnswer: Breast cancer is a collection of subtypes including luminal A/B, HER2-positive, and basal-like/triple-negative, each differing in molecular profiles, clinical behavior, and treatment responses.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What roles do genetic and epigenetic factors play in breast cancer?\nAnswer: Genetic alterations such as BRCA1/2 mutations and TP53, along with epigenetic modifications like DNA methylation and histone changes, are central to tumor initiation, progression, and metastasis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What are the risk factors associated with breast cancer?\nAnswer: Risk factors include endogenous factors like age, hormonal exposure, reproductive history, and genetic predisposition, as well as exogenous factors such as diet, alcohol, obesity, and environmental exposures.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What prevention strategies are recommended for breast cancer?\nAnswer: Prevention strategies include early screening (mammography, ultrasound, MRI), chemoprevention (tamoxifen, raloxifene), and lifestyle modifications (weight management, exercise).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: Why is early detection important in breast cancer?\nAnswer: Early detection is key to reducing mortality, with guidelines emphasizing clinical breast examination, self-examination, and advanced imaging studies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What are the treatment options for invasive breast cancer?\nAnswer: Treatment options include local treatments like breast-conserving surgery or mastectomy, and systemic treatments such as chemotherapy, endocrine therapy, and targeted therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What do the NCCN guidelines provide for breast cancer treatment?\nAnswer: The NCCN guidelines offer detailed algorithms for workup and treatment across different stages of breast cancer, encouraging participation in clinical trials.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: How does metastasis occur in breast cancer?\nAnswer: Metastasis may begin early, sometimes before the primary tumor is detected, and progresses in a homogeneous manner, with local recurrence being an indicator of further metastasis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What emerging therapies are being explored for breast cancer?\nAnswer: Emerging therapies include complementary approaches like herbal extracts and nutraceuticals, as well as ongoing research into gene therapy and stem-cell therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "64aba6551ed14b499648ef5242e173dc",
            "source": "Muhammad-AwerenessAndCurrentKnowledgeOfBreastCancer-2017",
            "main_category": "Muhammad"
        },
        "page_content": "Question: What is the importance of an integrated understanding in breast cancer management?\nAnswer: An integrated understanding from molecular biology to population-based epidemiology is crucial for improving prevention, early detection, and treatment outcomes in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What is the main objective of the study conducted by Ogundiran et al.?\nAnswer: The main objective of the study is to investigate the relationship between body fat distribution and the risk of invasive breast cancer in Nigerian women, particularly focusing on central adiposity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What methods were used to collect data in the study?\nAnswer: Data was collected through structured questionnaires administered by trained research nurses, capturing demographic, reproductive, and lifestyle information, along with anthropometric measurements following WHO MONICA guidelines.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What were the key findings regarding waist circumference and breast cancer risk?\nAnswer: Women in the highest quartile of waist circumference (90\u2013138 cm) had a significantly higher breast cancer risk, with an adjusted odds ratio (OR) of 2.39 compared to those in the lowest quartile (45\u201373 cm).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: How does hip circumference relate to breast cancer risk according to the study?\nAnswer: The study found an inverse association between hip circumference and breast cancer risk, with an adjusted OR of 0.36 for women with hip circumference greater than 108 cm compared to those with 54\u201392 cm.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What was the association between waist/hip ratio (WHR) and breast cancer risk?\nAnswer: A strong positive association was noted, with women in the highest quartile of WHR (>0.87) having an adjusted OR of 2.15 compared to those in the lowest quartile (<0.77).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What implications do the study's findings have for public health?\nAnswer: The findings highlight the importance of assessing fat distribution, not just overall obesity, when evaluating breast cancer risk, particularly in populations with different body composition profiles.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What limitations were noted in the study?\nAnswer: The study's limitations include potential recall and measurement biases due to its case-control design, the indirect nature of waist and hip circumference measurements of visceral fat, and the generalizability of findings being specific to the Nigerian population.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d209829f76104cc2a310f55591c6fc75",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future studies are needed to further elucidate the biological mechanisms behind the associations found and to explore the role of central adiposity in breast cancer across diverse populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What is the primary cause of deaths from breast cancer?\nAnswer: Breast cancer metastasis accounts for the majority of deaths from breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: Why is early detection of breast cancer metastasis important?\nAnswer: Early detection is crucial for the management and prediction of breast cancer progression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What emerging technique shows promise in detecting early stages of breast cancer metastasis?\nAnswer: The analysis of circulating tumor cells (CTCs) shows promising results in predicting and identifying early stages of breast cancer metastasis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What are the current methods for detecting breast cancer metastasis?\nAnswer: Detection methods include clinical manifestations, biopsies, radiological evaluations, imaging methods, and serum tumor markers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What role do circulating tumor cells (CTCs) play in breast cancer metastasis?\nAnswer: CTCs are tumor cells that circulate in the bloodstream and are important for predicting metastatic relapse and progression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What is the metastatic cascade?\nAnswer: The metastatic cascade is a series of sequential steps that tumor cells undergo, including local invasion, intravasation, dissemination, and colonization of distant organs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: How do tumor cells invade surrounding tissues?\nAnswer: Tumor cells invade by altering cell-to-cell adhesion and cell adhesion to the extracellular matrix (ECM), often involving cadherins.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What is the significance of the tumor microenvironment in metastasis?\nAnswer: The tumor microenvironment is critical for tumor cell proliferation and influences the progression from in situ to metastatic breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What is the 'seed and soil' theory in relation to metastasis?\nAnswer: The 'seed and soil' theory suggests that tumor cells (the 'seed') can only grow in a suitable environment (the 'soil').",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What factors contribute to angiogenesis in tumors?\nAnswer: Factors include genetic mutations, mechanical stresses, inflammatory processes, and hypoxia, leading to a shift towards pro-angiogenesis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "57001ad9a19e4fb1a5f597cf8e6dfea0",
            "source": "Olivia-BreastCancerMetastasis-2012",
            "main_category": "Olivia"
        },
        "page_content": "Question: What are the main treatment options for metastatic breast cancer?\nAnswer: Treatment options include standard chemotherapy and targeted therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the purpose of the WHO annex on anti-cancer medicines for breast cancer?\nAnswer: The purpose of the WHO annex is to provide guidance on the selection and use of anti-cancer medicines for breast cancer treatment and to detail the medicines included on the WHO Model List of Essential Medicines 2021.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the four distinct subtypes of breast cancer recognized in the document?\nAnswer: The four distinct subtypes of breast cancer recognized are Luminal A, Luminal B, Triple-negative, and HER2-positive.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the primary treatment for Hormone-Receptor Positive (ER+) Breast Cancer?\nAnswer: The primary treatment for Hormone-Receptor Positive (ER+) Breast Cancer is endocrine (hormone) therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the mainstay treatment for Triple-Negative Breast Cancer?\nAnswer: Chemotherapy is the mainstay treatment for Triple-Negative Breast Cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What are some examples of standard chemotherapy regimens for breast cancer mentioned in the document?\nAnswer: Examples of standard chemotherapy regimens include TC (docetaxel and cyclophosphamide), AC-T (doxorubicin and cyclophosphamide followed by paclitaxel), CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), and FAC/FEC (5-fluorouracil, doxorubicin, and cyclophosphamide).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What supportive care measures are emphasized in the document for breast cancer treatment?\nAnswer: Supportive care measures include antiemetics, growth factors, bone-modifying agents, and potentially anti-depressants to manage side effects and maintain patient quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the significance of the WHO Model List of Essential Medicines in breast cancer treatment?\nAnswer: The WHO Model List of Essential Medicines ensures that the most important anti-cancer and supportive medications are available globally, even in low-resource settings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: How does the document suggest adapting breast cancer treatment protocols?\nAnswer: The document suggests that treatment may be modified based on individual patient factors such as toxicity profile, comorbidities, and cost considerations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "64da2ecc0f9c4154a13c2ff8bef7ea6a",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the conclusion of the WHO annex regarding breast cancer treatment?\nAnswer: The conclusion emphasizes the importance of integrating evidence-based chemotherapy, endocrine therapy, and targeted treatments with appropriate supportive care to ensure effective and feasible treatment protocols.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the definition of early diagnosis in cancer care?\nAnswer: Early diagnosis is defined as the early identification of cancer in patients who already present with symptoms or signs suggestive of cancer, focusing on detecting cancer at the earliest possible stage to improve survival and quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: How does early diagnosis differ from screening?\nAnswer: Early diagnosis targets individuals with symptoms, while screening aims to identify unrecognized cancer in an apparently healthy population through systematic testing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the key differences in participant volume between early diagnosis and screening programs?\nAnswer: Early diagnosis is limited to symptomatic individuals with relatively low volume, whereas screening programs involve the entire target population, often with participation rates 50\u2013100 times higher.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the health system requirements for early diagnosis?\nAnswer: Early diagnosis requires facilities and human resources for prompt clinical evaluation, pathology, radiology, staging, and treatment access.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the process involved in early diagnosis?\nAnswer: The early diagnosis process includes increasing public awareness of cancer symptoms, ensuring rapid clinical evaluation and accurate diagnosis, and providing timely access to treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the potential benefits and harms of screening programs?\nAnswer: Potential benefits of screening include reduced disease incidence and earlier diagnosis, while harms may include overdiagnosis, psychological distress, and complications from further testing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What impact does early diagnosis have on cancer outcomes and mortality?\nAnswer: Early diagnosis linked to prompt treatment leads to earlier stage presentation and reduced cancer mortality, as evidenced by historical data showing declines in breast cancer mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What recommendations are made for integrating early diagnosis into cancer control?\nAnswer: Early diagnosis should be an integral part of comprehensive cancer control programs, ensuring adequate capacity for diagnosis and treatment before introducing population-wide screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the strategic importance of strengthening early diagnosis systems?\nAnswer: Strengthening early diagnosis systems is critical to improving cancer outcomes, especially in resource-limited settings, and is a prerequisite for effective screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "c17acb54e76c4653855b92e63e090275",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What next steps are suggested for countries regarding early diagnosis and screening services?\nAnswer: Countries should perform comprehensive situation analyses to assess current capacity, identify barriers, and guide the implementation or expansion of early diagnosis and screening services.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What is the prognosis for patients with oligometastatic breast cancer (OMBC)?\nAnswer: Patients with OMBC have a significantly better prognosis compared to those with metastatic breast cancer (MBC), with overall survival rates of 59.2% at 10 years and 34.1% at 20 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What defines oligometastatic breast cancer (OMBC)?\nAnswer: OMBC is characterized by involvement of one or two organs with metastatic lesions, fewer than five lesions per organ, and lesion diameter less than 5 cm.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What treatment approaches are typically used for OMBC?\nAnswer: Patients with OMBC are generally treated with systemic chemotherapy first, followed by local therapy (surgery or radiation) if they achieve a complete or partial response.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What factors are associated with better prognosis in OMBC?\nAnswer: Factors favoring better prognosis include single organ involvement with metastasis, administration of local treatment, and shorter disease-free interval after initial treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What is the definition of clinical cure in the context of breast cancer?\nAnswer: Clinical cure is defined as a sustained relapse-free interval (RFI) and no recurrence of cancer after achieving complete response (CR) or no evidence of clinical disease (NED).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: How does the survival rate of OMBC compare to that of MBC?\nAnswer: The survival rate for OMBC is markedly higher than that for MBC, which has overall survival rates as low as 1-3% at 20 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What percentage of OMBC patients achieved clinical cure in the study?\nAnswer: In the study, 4% of OMBC patients were considered to have achieved clinical cure, remaining relapse-free for their entire survival periods.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What are the overall response rates (ORR) for systemic therapy in OMBC patients?\nAnswer: The overall response rate (ORR) for systemic therapy in OMBC patients was 95.6%, with complete response (CR) in 48.5% and partial response (PR) in 47.1% of cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What is the significance of local therapy in the treatment of OMBC?\nAnswer: Local therapy is significant as it can help maintain complete response (CR) or induce no evidence of clinical disease (NED), contributing to better long-term outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What are the estimated outcomes for OMBC based on literature?\nAnswer: Literature indicates overall survival rates for OMBC of 35-73% at 10 years and 26-52% at 20 years, with relapse-free rates of 27-42% at both 10 and 20 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "bb84c9c70cd94c338bf1aad71c550cb3",
            "source": "Personal-control-over-the-cure-of-breast-cancer",
            "main_category": "Personal"
        },
        "page_content": "Question: What role does the number of involved organs play in the prognosis of OMBC?\nAnswer: Patients with single organ involvement have significantly better outcomes compared to those with two involved organs, with higher overall survival and relapse-free rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What are the 'invisible scars' referred to in the article?\nAnswer: The 'invisible scars' refer to the emotional, psychological, and social impacts of breast cancer treatments that extend beyond physical changes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: How does the article critique the dominant narratives of breast cancer survivorship?\nAnswer: The article critiques the dominant narratives that celebrate survivorship as a 'transformative journey' by highlighting the ongoing struggles, such as chronic pain and altered body image, faced by many survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What emotional and psychological impacts do breast cancer treatments have on survivors?\nAnswer: Breast cancer treatments can lead to depression, anxiety, and disrupted sexual identity, which are often not captured by biomedical assessments but are significantly felt in survivors' daily lives.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What role do gendered dimensions play in the experience of breast cancer treatment?\nAnswer: Cultural expectations about femininity and the importance of breasts to a woman's identity influence how survivors experience treatment side effects, leading to feelings of loss and diminished sexual desirability.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What does Porroche-Escudero suggest regarding medical authority and narratives?\nAnswer: Porroche-Escudero suggests that biomedical and mass media discourses often silence the 'invisible scars' by promoting overly optimistic narratives of recovery, marginalizing the lived experiences of survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What implications does the article have for patient support?\nAnswer: The article emphasizes the need to recognize invisible scars to develop holistic care practices that address the emotional, psychological, and social needs of survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What methodological approach does the article use?\nAnswer: The article employs ethnographic insights and critical analysis of cultural narratives, referencing various scholarly works on survivorship and gendered body politics.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "f0434fb6af674c32ace3383f4fdeaf32",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What conclusion does Porroche-Escudero reach regarding breast cancer survivorship?\nAnswer: Porroche-Escudero concludes that a broader understanding of breast cancer survivorship is necessary, one that acknowledges and addresses the 'invisible scars' to improve care and validate survivors' complex realities.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What is the general prognosis for metastatic breast cancer (MBC)?\nAnswer: Metastatic breast cancer is generally considered incurable, with median survival reported to be between 8 to 24 months, and long-term survival rates beyond 3 to 5 years being very low, often around 1-3% at 20 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What defines oligometastatic breast cancer (OMBC)?\nAnswer: Oligometastatic breast cancer is characterized by involvement of one or two organs with metastatic lesions, fewer than five lesions per organ, and lesion diameter less than 5 cm.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What treatment strategies are typically employed for patients with OMBC?\nAnswer: Patients with OMBC are generally treated with systemic chemotherapy first, followed by local therapy (surgery or radiation) if they achieve a complete or partial response.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What were the median overall survival (OS) and relapse-free interval (RFI) for patients with OMBC in the study?\nAnswer: The median overall survival was 185.0 months, and the median relapse-free interval was 48.0 months.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What factors were identified as favorable for prognosis in OMBC?\nAnswer: Favorable factors for prognosis included single organ involvement with metastasis, administration of local treatment, and shorter disease-free interval.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What percentage of patients achieved clinical cure in the study?\nAnswer: In the study, 4% of patients (3 cases) achieved what was defined as clinical cure, remaining relapse-free for their entire lifespan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: How does the prognosis of OMBC compare to that of MBC?\nAnswer: The prognosis for OMBC is significantly better than that for MBC, with long-term survival rates for OMBC being 35-73% at 10 years and 26-52% at 20 years, compared to much lower rates for MBC.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What is the significance of local therapy in the treatment of OMBC?\nAnswer: Local therapy is significant in OMBC as it can help achieve no evidence of clinical disease (NED) and improve overall survival rates, especially when combined with systemic therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What are the implications of the findings for future research on OMBC?\nAnswer: The findings suggest that further prospective studies are warranted to better characterize OMBC and improve prognosis in MBC, as well as to explore the potential for clinical cure.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "6d25379b8e7b4af28138642d0c646aa0",
            "source": "Possible-Clinical-Cure-of-Metastatic-Breast-Cancer-Lessons-from-30-Year-Experience-and-Review",
            "main_category": "Possible"
        },
        "page_content": "Question: What role does the number of involved organs play in the prognosis of OMBC?\nAnswer: Patients with single organ involvement showed significantly better outcomes compared to those with two involved organs, indicating that fewer metastatic sites correlate with improved prognosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What has surpassed lung cancer as the most common cause of cancer deaths worldwide?\nAnswer: Breast cancer has surpassed lung cancer as the most common cause of cancer deaths worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: How has breast cancer treatment evolved over the years?\nAnswer: Breast cancer treatment has evolved from conventional surgical approaches and radiotherapy to local and systemic adjuvant therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What is the significance of adjuvant systemic therapy in breast cancer treatment?\nAnswer: Adjuvant systemic therapy is effective in both distant and local recurrences, significantly improving early breast cancer prognosis and reducing mortality rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What percentage of breast cancer patients present with localized tumors?\nAnswer: 61% of breast cancer patients present with localized tumors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What are the main types of adjuvant therapies discussed in the document?\nAnswer: The main types of adjuvant therapies discussed include chemotherapy, endocrine therapy, targeted therapy, bone-modifying drug therapy, and adjuvant intensive therapy after neoadjuvant therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What role does chemotherapy play in the treatment of early breast cancer?\nAnswer: Chemotherapy plays a crucial role in prolonging survival and improving prognosis in early breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What are the benefits of anthracycline-containing adjuvant chemotherapy regimens?\nAnswer: Anthracycline-containing regimens are often recommended for node-positive or high-risk node-negative breast cancer and have shown improved disease-free survival and overall survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What is the impact of dual-targeted therapy in HER2-positive breast cancer?\nAnswer: Dual-targeted therapy has been shown to decrease recurrence rates and prolong invasive disease-free survival in HER2-positive breast cancer patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What is the significance of adjuvant endocrine therapy for HR-positive breast cancer?\nAnswer: Adjuvant endocrine therapy is crucial for HR-positive breast cancer, significantly reducing the risk of recurrence and improving survival outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What are the findings of the KATHERINE study regarding adjuvant therapy?\nAnswer: The KATHERINE study revealed that adjuvant intensive T-DM1 therapy after surgery improved invasive disease-free survival in HER2-positive breast cancer patients who did not achieve a pathologic complete response after neoadjuvant therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What challenges are associated with chemotherapy for triple-negative breast cancer (TNBC)?\nAnswer: Chemotherapy for TNBC is associated with challenges such as adverse reactions and drug resistance.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 12,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What is the role of bisphosphonates in the adjuvant therapy of early breast cancer?\nAnswer: Bisphosphonates have been explored for their potential in bone protection and treatment of breast cancer bone metastasis, showing marginal benefits in postmenopausal early breast cancer patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 13,
            "id": "7086514bc1184c53b5198218edcfe2b6",
            "source": "Research-Status-of-Systemic-Adjuvant Therapy-for-Early-Breast-Cancer",
            "main_category": "Research"
        },
        "page_content": "Question: What future prospects are suggested for adjuvant therapy in early breast cancer?\nAnswer: Future prospects include the exploration of anthracycline-free regimens, personalized treatment approaches, and the continuous investigation of new drugs and treatment regimens to improve therapeutic effects and survival benefits.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What do the NCCN Clinical Practice Guidelines for Invasive Breast Cancer emphasize?\nAnswer: The guidelines emphasize that clinical trials are the preferred treatment option at all stages of breast cancer and that recommendations are categorized by the level of evidence and consensus.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What is the significance of breast cancer statistics mentioned in the document?\nAnswer: Breast cancer is the most common malignancy among women, with an estimated 209,060 new cases and around 40,230 deaths in 2010, highlighting the importance of early detection and improved treatment methods.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What are some nonmodifiable and modifiable risk factors for invasive breast cancer?\nAnswer: Nonmodifiable factors include female gender, increased age, and family history of breast cancer. Modifiable factors include obesity, alcohol consumption, sedentary lifestyle, and prolonged exposure to hormones.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What does the clinical workup for suspected invasive breast cancer include?\nAnswer: The clinical workup includes a detailed history and physical examination, laboratory studies, imaging studies, pathology review, and genetic counseling for high-risk patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What are the major treatment modalities for invasive breast cancer?\nAnswer: Major treatment modalities include surgical management (lumpectomy or mastectomy), axillary management (sentinel lymph node biopsy or axillary dissection), radiation therapy, and systemic therapy (endocrine, chemotherapy, and targeted therapy).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: How does the NCCN categorize recommendations based on evidence levels?\nAnswer: Recommendations are categorized as Category 1 (high-level evidence), Category 2A (lower-level evidence with uniform consensus), Category 2B (lower-level evidence with nonuniform consensus), and Category 3 (recommendations with major disagreement).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What is the role of clinical trials in breast cancer management according to the guidelines?\nAnswer: Clinical trials are emphasized as crucial for advancing knowledge and improving outcomes, offering patients access to cutting-edge treatments and contributing to the development of future guidelines.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "3ec0810d9f62484ab024230c0e296663",
            "source": "Robert-InvasiveBreastCancer-2011",
            "main_category": "Robert"
        },
        "page_content": "Question: What is the overall goal of the NCCN Clinical Practice Guidelines for Invasive Breast Cancer?\nAnswer: The guidelines aim to provide a detailed, evidence-based framework for managing breast cancer, optimizing outcomes, and improving survival through a multidisciplinary approach and clinical trial participation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What is the emotional impact of a breast cancer diagnosis?\nAnswer: A breast cancer diagnosis is typically anxiety-provoking and traumatic, often historically viewed as a 'death sentence.' Despite improved survival rates, patients and families experience high levels of distress, anxiety, and depression, especially in the early phases after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: How does age affect breast cancer prognosis?\nAnswer: Breast cancer is the most common cancer in women, with risk increasing with age. Young women often face more aggressive disease, leading to a higher risk of recurrence and mortality compared to older women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What role does social support play in coping with breast cancer?\nAnswer: Social support is crucial for coping with breast cancer, encompassing emotional, informational, and instrumental dimensions. Strong support networks can alleviate the psychological burden on patients and their families.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What specific challenges do breast cancer patients face?\nAnswer: Breast cancer patients often experience significant emotional distress, body image issues, and impacts on relationships. Major depression prevalence ranges from 10% to 25%, particularly high during the first year after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: How does breast cancer affect intimate relationships?\nAnswer: The emotional and psychosocial challenges of breast cancer extend to intimate partners and family dynamics, with distress in patients often mirrored by their partners. Supportive spousal relationships can mitigate anxiety and depression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What research findings are highlighted regarding partner and family dynamics?\nAnswer: Research indicates that family members, especially intimate partners, experience significant emotional burden. Effective communication within couples is associated with lower distress and higher marital satisfaction.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What are the implications for interventions and policy regarding breast cancer support?\nAnswer: The chapter advocates for interventions that enhance spousal and family support, encourage couple-focused counseling, and address the psychosocial needs of patients and their close relations to improve overall outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "931aa526041043c796c296ac09fcdeac",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What is the conclusion regarding the impact of breast cancer on patients and their families?\nAnswer: Breast cancer affects physical health, mental well-being, body image, and relationships. Strong social support, particularly from intimate partners, is vital in mitigating adverse effects, though many still experience significant distress.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the main focus of the Copenhagen Consensus Center Report?\nAnswer: The report focuses on recommended interventions for screening and treatment of non-communicable diseases (NCDs) in Rajasthan, India.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What are the key health challenges identified in Rajasthan regarding NCDs?\nAnswer: Despite lower rates of overweight/obesity, Rajasthan faces low screening rates for cancers and challenges in health system capacity, quality of care, and access.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What age group is targeted for the interventions proposed in the report?\nAnswer: The interventions uniformly target individuals aged 30\u201369 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the expected impact of the cardiovascular disease (CVD) screening and treatment intervention?\nAnswer: The intervention is projected to reduce high-risk CVD deaths by approximately 20% over a 13-year period.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What treatment is recommended for diabetes management in the report?\nAnswer: The report recommends routine screening for elevated blood sugar followed by treatment with Metformin for those identified with diabetes or prediabetes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: How does the report suggest addressing cervical cancer screening?\nAnswer: A screen-and-treat approach using Visual Inspection with Acetic Acid and Lugol's Iodine (VIA/VILI) is recommended for cervical cancer screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the projected outcome of the breast cancer screening intervention?\nAnswer: The intervention is projected to avert approximately 16% of breast cancer deaths.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What are the overall policy recommendations from the report?\nAnswer: The report recommends prioritizing secondary prevention, implementing targeted screening programs, and ensuring comprehensive policy planning for effective early detection and treatment of NCDs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the significance of the benefit-cost analysis conducted in the report?\nAnswer: The analysis indicates that the proposed interventions are highly cost-effective and can yield significant public health benefits in Rajasthan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "e9a72b85e105484b9881e7fc77f971f8",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What role do community health workers play in the proposed interventions?\nAnswer: Community health workers are central to outreach and mobilization for the interventions, leveraging local resources for awareness-raising.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What is the traditional treatment regimen for early-stage breast cancer?\nAnswer: The traditional treatment regimen involves a conventional fractionation scheme of approximately 2 Gy per fraction over 25 fractions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What is hypofractionated radiotherapy?\nAnswer: Hypofractionated radiotherapy employs larger doses per fraction over fewer treatment sessions, which has gained attention in recent years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What is the significance of the \u03b1/\u03b2 ratio in radiotherapy?\nAnswer: The \u03b1/\u03b2 ratio is a radiobiological parameter that reflects a tissue's sensitivity to fraction size, influencing how tissues respond to radiation damage.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What was the primary goal of the study?\nAnswer: The primary goal was to analyze data from multiple large randomized clinical trials to estimate the \u03b1/\u03b2 ratio for breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What was the average \u03b1/\u03b2 ratio found for breast cancer in the study?\nAnswer: The study found an average \u03b1/\u03b2 ratio of approximately 2.88 Gy for breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What are the implications of a lower \u03b1/\u03b2 ratio for breast cancer treatment?\nAnswer: A lower \u03b1/\u03b2 ratio suggests that breast tumors are more responsive to increased dose per fraction, supporting the use of hypofractionated treatment schedules.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What are some proposed hypofractionated treatment regimens based on the study's findings?\nAnswer: Proposed regimens include 2.26 Gy per fraction over 20 fractions, 3.34 Gy per fraction over 10 fractions, and 4.93 Gy per fraction over 5 fractions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What are the potential benefits of hypofractionated regimens?\nAnswer: Benefits include improved patient convenience, potential for reduced toxicity, cost and resource efficiency, and shorter overall treatment times.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What limitations did the study acknowledge?\nAnswer: The study acknowledged variability in clinical data, simplified modeling assumptions, and the need for prospective validation through ongoing clinical trials.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "8b482ff7f4b74bcaba688645f3078d25",
            "source": "Sharon-Is\u03b1\u03b2ForBreastCancerReallyLow-2011",
            "main_category": "Sharon"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future research should focus on long-term follow-up of patients treated with hypofractionated regimens to confirm benefits and refine treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What is the main focus of the study conducted by Slattery et al.?\nAnswer: The study investigates whether a family history of breast cancer affects survival outcomes among women diagnosed with the disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What data sources were utilized in the study?\nAnswer: The study utilized the Utah Cancer Registry and the Utah Population Database, which provided detailed genealogy data from Mormon pioneer families.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: How many women were included in the study population?\nAnswer: The analysis focused on 3,578 women diagnosed with a first primary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What definitions of family history were considered in the study?\nAnswer: Family history was defined in multiple ways, including having a first-degree relative with breast cancer, specifically a mother with breast cancer, and a total familial risk measure calculated as a kin-weighted score.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What statistical methods were used to analyze survival time?\nAnswer: Kaplan\u2013Meier methods were used to estimate survival time, and Cox proportional hazards models were employed to calculate hazard rate ratios (HRRs) with adjustments for potential confounders.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What were the key findings regarding family history and survival?\nAnswer: Women with a family history of breast cancer had poorer survival compared to those without such a history, particularly younger women diagnosed at age 50 or younger.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What was the hazard rate ratio (HRR) associated with having a mother with breast cancer?\nAnswer: Having a mother with breast cancer was associated with an HRR of approximately 1.55.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: Did the study find any protective effects of family history in older women?\nAnswer: Yes, certain family history indicators, such as having a sister with breast cancer, did not show a consistent association with poorer survival and might suggest a slight protective effect among older women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What conclusion did the authors draw regarding family history and breast cancer survival?\nAnswer: The study concluded that a positive family history of breast cancer is associated with poorer survival, especially in younger women diagnosed with the disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What limitations did the study acknowledge?\nAnswer: The study acknowledged that the population comes from Utah, which might limit generalizability, and that incomplete family history may occur if relatives moved out of state.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 11,
            "id": "d911ed8a11b049168792fb135d25b440",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What implications do the findings have for breast cancer research?\nAnswer: The findings suggest that family history may capture underlying genetic or environmental factors affecting both the risk of developing breast cancer and survival outcomes, highlighting the need for further research.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What is the main focus of the study discussed in the document?\nAnswer: The study focuses on whether following a diabetes risk reduction diet (DRRD) after a breast cancer diagnosis is linked with improved survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: How many participants were involved in the study?\nAnswer: The study included 8,482 women diagnosed with stage I\u2013III breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What dietary assessment method was used in the study?\nAnswer: Participants provided detailed dietary information using validated food frequency questionnaires.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What does a higher DRRD score indicate?\nAnswer: A higher DRRD score indicates better adherence to a diet that may reduce the risk of developing type 2 diabetes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What were the key findings regarding mortality rates?\nAnswer: Women with the highest DRRD scores had about a 20% lower risk of dying from breast cancer and a 34% lower risk of dying from any cause compared to those with the lowest scores.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What impact did improving DRRD scores have on mortality?\nAnswer: Women who improved their DRRD score from before to after diagnosis experienced a significant reduction in both breast cancer-specific and overall mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: Did the study's findings remain consistent after adjusting for other factors?\nAnswer: Yes, the associations remained strong even after adjusting for factors such as age, body weight changes, physical activity, smoking, treatment received, and socioeconomic status.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d9aa6cba080a455390cd5d28289dab64",
            "source": "Tengteng-DisabetsRiskReductionAndSurvivalAfterBreastCancerDiagnosis-2013",
            "main_category": "Tengteng"
        },
        "page_content": "Question: What conclusion can be drawn from the study's findings?\nAnswer: The findings suggest that adopting a diet aimed at reducing diabetes risk after a breast cancer diagnosis may improve survival outcomes for breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What is the main focus of the article 'A Crisis of Erasure'?\nAnswer: The article examines how breast cancer health information is constructed within mainstream health and library contexts, particularly focusing on the invisibility and erasure of transgender and gender-nonconforming (TGNC) populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What are the consequences of the 'crisis of erasure' for TGNC individuals?\nAnswer: The crisis of erasure creates informational boundaries, limits access, and reduces the quality of care for transgender and gender-nonconforming people who may be at risk for or are living with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What methodology did the authors use in their study?\nAnswer: The study involved a comprehensive literature search across multiple databases and a thematic analysis conducted by three researchers who reviewed and coded the selected literature.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What are the three key themes identified as barriers for TGNC individuals in accessing breast cancer health information?\nAnswer: The three key themes are Access, Erasure, and Quality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What challenges do TGNC patients face in accessing health information?\nAnswer: TGNC patients face challenges such as difficulties in finding relevant information, limited appointment time with providers, and structural constraints within healthcare settings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: How does the concept of 'erasure' affect TGNC individuals in the context of breast cancer information?\nAnswer: Erasure occurs as breast cancer information is largely constructed around normative ideas of femininity, marginalizing TGNC individuals and failing to reflect their experiences.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What recommendations do the authors make for improving health information access for TGNC individuals?\nAnswer: The authors recommend inclusive LIS education, developing robust TGNC resources and services, and advocating for policy changes to support equitable access to health services.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "def3232544fc4c47b9cb425825f399fd",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What is the conclusion of the article regarding the framing of breast cancer?\nAnswer: The article concludes that framing breast cancer as an exclusively female disease creates an information boundary that erases TGNC experiences, limiting access to accurate health information and negatively impacting health outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What is the main focus of the study conducted by Slattery, Berry, and Kerber?\nAnswer: The study investigates whether the survival of women diagnosed with breast cancer is influenced by their family history of the disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What data source was used in the study to assess family history?\nAnswer: The study used the Utah Population Database, which links genealogy, cancer registry, and vital statistics data.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: How many women were included in the study population?\nAnswer: The analysis included 4,083 women diagnosed with a first primary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What statistical methods were employed to analyze survival data?\nAnswer: Survival analysis was conducted using Kaplan\u2013Meier estimates and Cox proportional hazards models.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What key finding was reported regarding women with a family history of breast cancer?\nAnswer: Women with a family history of breast cancer tended to have shorter median survival compared to those without such a history.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: How did family history affect survival in women diagnosed before age 50?\nAnswer: The effect of family history was most pronounced in women diagnosed at or before age 50, showing a statistically significant increased risk of death.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What limitations did the study acknowledge?\nAnswer: The study acknowledged limitations such as incomplete family history data, possible misclassification, and the population being potentially unrepresentative of all U.S. populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What implications do the study's findings have for breast cancer prognosis?\nAnswer: The research underscores the importance of considering detailed family history when evaluating prognosis in breast cancer patients and suggests the need for tailored treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "e7f135ab55054d2f893325a86aceab60",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What conclusion did the authors reach regarding family history and breast cancer survival?\nAnswer: The study concluded that certain aspects of family history, especially having a mother with breast cancer or a large number of affected female relatives, are associated with poorer survival among women diagnosed with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What is the most common cause of cancer death among women worldwide?\nAnswer: Breast cancer is the most common cause of cancer death among women worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What are some established risk factors associated with breast cancer?\nAnswer: Established risk factors include early menarche, late menopause, obesity in postmenopausal women, and high concentrations of endogenous oestradiol.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: How does childbearing affect breast cancer risk?\nAnswer: Childbearing reduces breast cancer risk, especially for women with an early first birth and multiple children.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What is the relationship between age and breast cancer incidence?\nAnswer: The incidence of breast cancer increases rapidly with age, particularly during reproductive years, and continues to rise slowly after age 50.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: How do breast cancer rates vary internationally?\nAnswer: Breast cancer incidence and mortality rates vary dramatically, with higher rates in developed nations and lower rates in developing countries.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What impact does alcohol consumption have on breast cancer risk?\nAnswer: Alcohol consumption is positively associated with breast cancer risk, increasing by about 10% for each 10 grams consumed daily.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What role do endogenous hormones play in breast cancer risk?\nAnswer: Higher levels of oestradiol in postmenopausal women are associated with a doubled risk of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What lifestyle changes can help reduce breast cancer risk?\nAnswer: Reducing alcohol consumption, avoiding obesity, maintaining regular physical activity, and breastfeeding can significantly reduce breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What is the effect of hormonal therapies on breast cancer risk?\nAnswer: Hormonal therapies, such as oral contraceptives and hormone replacement therapy, can increase breast cancer risk, but careful use can minimize this risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "83f4e251f6714ea99563614114904925",
            "source": "Timothy-EpidemiologyOfBreastCancer-2001",
            "main_category": "Timothy"
        },
        "page_content": "Question: What genetic factors are associated with breast cancer?\nAnswer: Some families exhibit an inherited genetic predisposition, with high-risk mutations in genes like BRCA1, BRCA2, P53, PTEN, and ATM accounting for a smaller portion of cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What is the focus of the study conducted by Tolaney et al.?\nAnswer: The study focuses on the combination of eribulin and pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What are the main characteristics of metastatic triple-negative breast cancer (mTNBC)?\nAnswer: mTNBC is an aggressive disease with limited effective treatment options, particularly beyond first-line therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What was the design of the study?\nAnswer: The study was an open-label, single-arm phase Ib/II trial conducted at 18 US sites.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What were the eligibility criteria for patients in the study?\nAnswer: Eligible patients were \u226518 years old with mTNBC, measurable disease per RECIST 1.1, ECOG performance status \u22641, and \u22642 prior systemic therapies in the metastatic setting.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What treatment regimen was administered to the patients?\nAnswer: Patients received intravenous eribulin 1.4 mg/m\u00b2 on days 1 and 8 and pembrolizumab 200 mg IV on day 1 of each 21-day cycle.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What were the primary endpoints of the study?\nAnswer: The primary endpoints were safety, tolerability, and objective response rate (ORR) as assessed by independent review.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What were the results regarding the overall objective response rate (ORR)?\nAnswer: The overall ORR was 23.4%, with complete responses in 4.8% and partial responses in 18.6% of patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: How did the ORR differ between first-line and later-line treatment groups?\nAnswer: In the first-line group (Stratum 1), the ORR was 25.8%, while in the later-line group (Stratum 2), it was 21.8%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What was the median progression-free survival (PFS) and overall survival (OS) reported in the study?\nAnswer: The median PFS was 4.1 months and the median OS was 16.1 months.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "18b8eeda5f4a4f66b1951751fc9930d1",
            "source": "Tolaney-EribulinPlusPembrolizumab-2021",
            "main_category": "Tolaney"
        },
        "page_content": "Question: What conclusion did the authors draw regarding the combination of eribulin and pembrolizumab?\nAnswer: The authors concluded that eribulin plus pembrolizumab was generally well tolerated and showed promising antitumor activity in mTNBC, particularly in patients with PD-L1-positive tumors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What is the conclusion regarding the benefit of axillary treatment in early breast cancer patients?\nAnswer: Effective axillary treatment should still be considered an essential aspect of primary treatment, as it may cure approximately 5-10% of patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: How has the understanding of breast cancer spread influenced the treatment of the axilla?\nAnswer: Theories on breast cancer spread have evolved, with earlier beliefs of direct permeation being replaced by the concept of noncontiguous spread by embolization, leading to questions about the necessity of axillary treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What evidence challenges the sequential spread theory of breast cancer?\nAnswer: Clinical observations show that about 25% of patients with histologically negative axillary nodes develop distant metastases, suggesting that cancer can spread directly from the primary site to distant sites.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What were the findings of the NSABP Study B-04 regarding axillary treatment?\nAnswer: The study found that axillary treatment did not provide a significant advantage in freedom from distant relapse or survival, indicating that the number of patients who might benefit from axillary treatment is small.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What is the estimated percentage of patients who might benefit from effective axillary treatment?\nAnswer: Approximately 5-10% of patients with early breast cancer may benefit from effective axillary treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What constitutes effective axillary treatment according to the document?\nAnswer: Effective axillary treatment is generally accepted to involve thorough dissection without the need for pectoral muscle resection, ensuring optimal tumor control and prognosis assessment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What is the significance of axillary dissection in breast cancer treatment?\nAnswer: Axillary dissection allows for the determination of the histological status of lymph nodes, which is crucial for estimating prognosis and deciding on adjuvant systemic therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "c8afe34a618b45fda645646e2a734824",
            "source": "Treatment-of-the-axilla-in-patients-with-early-breast-cancer",
            "main_category": "Treatment"
        },
        "page_content": "Question: What does the document suggest about the long-term effects of axillary treatment on survival?\nAnswer: The document suggests that the survival benefits of axillary treatment may not become apparent for many years, and that effective treatment could lead to a cure in a small percentage of patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What is the focus of Part I of the clinical review on breast cancer management?\nAnswer: Part I focuses on preventive strategies, risk reduction, early detection, and improvements in local therapy, including surgery and radiotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What modifiable risk factors are linked to increased breast cancer risk?\nAnswer: Post-menopausal obesity, sedentary lifestyle, high alcohol consumption, and lower rates of breastfeeding are linked to increased breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: How do Selective Oestrogen Receptor Modulators (SERMs) like tamoxifen and raloxifene contribute to breast cancer prevention?\nAnswer: Tamoxifen can reduce the incidence of invasive breast cancer by around 38% among high-risk women, while raloxifene shows a similar preventive effect in post-menopausal women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What are the benefits and limitations of mammographic screening for breast cancer?\nAnswer: Mammographic screening can lead to a modest mortality reduction (~15%), but concerns about overdiagnosis exist.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What surgical options are discussed in the management of breast cancer?\nAnswer: Breast-conserving surgery is preferred when feasible, while mastectomy is reserved for larger or multifocal tumors or patient preference.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What advancements in radiotherapy are highlighted in the review?\nAnswer: Optimized schedules, including accelerated and hypofractionated regimens, and emerging techniques like intraoperative radiotherapy and brachytherapy are discussed.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What impact have recent advances in breast cancer management had on mortality rates?\nAnswer: Improvements in screening, local management, and multimodal treatment have contributed to a decline in breast cancer mortality by over 25% in recent decades.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What practical tips are provided for non-specialists regarding breast cancer assessment?\nAnswer: Patients with potential breast abnormalities should be referred promptly to a specialist, and women with significant family histories should receive comprehensive genetic risk assessments.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "9e496ca954224837b6e483b96b56d100",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What future directions for breast cancer research are suggested in the review?\nAnswer: Ongoing research is needed to define optimal screening strategies, refine surgical techniques, and understand interactions between environmental risk factors and genetic predispositions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What is the main focus of Emily Waples' essay 'Emplotted Bodies'?\nAnswer: The essay explores how breast cancer is represented in contemporary feminist discourse, interweaving personal narrative with cultural analysis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: How does Waples critique dominant breast cancer narratives?\nAnswer: Waples critiques the prevailing 'survivor' narrative for presenting a homogenized image that marginalizes diverse experiences, particularly those of younger women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What distinction does Waples make between postfeminism and third-wave feminism?\nAnswer: Waples critiques postfeminism for its apolitical nature and presents third-wave feminism as a transformative approach that can reframe breast cancer narratives in an intersectional context.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What role does narrative construction play in Waples' analysis?\nAnswer: Waples examines how narrating breast cancer serves to organize lived experiences and critiques the dominant survival plot that overlooks ongoing pain and intersectional factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: How does Waples address the impact of digital media on breast cancer narratives?\nAnswer: Waples discusses how online platforms allow for more nuanced and diverse accounts of breast cancer, challenging the sanitized survivor story.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What does Waples argue is necessary for the evolution of breast cancer narratives?\nAnswer: Waples argues that narratives must evolve to be inclusive and intersectional, acknowledging vulnerability and the political nature of embodied experiences.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "6d9be67759634623b4a5a4006c559494",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What is the conclusion of Waples' essay regarding feminist engagement with breast cancer narratives?\nAnswer: Waples calls for a rearticulation of breast cancer narratives that reflect the diverse realities of young women, moving beyond monolithic survival stories.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is the annual incidence of invasive breast cancer diagnoses in the United States?\nAnswer: Each year, more than 250,000 women in the United States are diagnosed with invasive breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is the second most common cause of cancer death among women?\nAnswer: Breast cancer is the second most common cause of cancer death among women in the United States.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What are the primary risk factors for breast cancer?\nAnswer: Advancing age, female sex, genetic mutations (BRCA 1 and 2), history of ductal carcinoma in situ (DCIS), high body mass index (BMI), late first birth, early menarche, family history of breast or ovarian cancer, late menopause, and postmenopausal hormone therapy use.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What are the main subtypes of breast cancer?\nAnswer: The main subtypes of breast cancer include Luminal A, Luminal B, HER-2 positive, and Triple-negative (basal).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is Triple-Negative Breast Cancer (TNBC)?\nAnswer: Triple-Negative Breast Cancer (TNBC) refers to malignancies that do not express hormone receptors or HER-2, accounting for about 12% of breast cancer cases.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What are the initial imaging modalities used for breast cancer diagnosis?\nAnswer: Mammography and ultrasonography are the initial imaging modalities used for breast cancer diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is the recommended age for women to start screening mammography according to the USPSTF?\nAnswer: The US Preventive Services Task Force (USPSTF) recommends screening mammography for women ages 50 to 74.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What surgical options are available for breast cancer treatment?\nAnswer: Surgical options include lumpectomy, mastectomy, or bilateral mastectomy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is the significance of hormone receptor status in breast cancer treatment?\nAnswer: Hormone receptor status is crucial as it determines the use of hormone-blocking therapy for hormone receptor-positive breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "96ef04459b0c4ebcb4d0f43150fceb2e",
            "source": "Watkins-OverviewOfBreastCancer-2019",
            "main_category": "Watkins"
        },
        "page_content": "Question: What is the role of biopsy in breast cancer diagnosis?\nAnswer: Breast cancer is diagnosed through biopsy, which can be performed using ultrasound-guided core needle biopsy, excisional biopsy, or stereotactic biopsy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What was the main objective of the study on breast cancer patients?\nAnswer: The main objective was to identify clinical and pathological features observable at first presentation that predicted a favorable long-term prognosis for patients with invasive breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: How many patients survived for more than 20 years after breast cancer diagnosis?\nAnswer: 51 patients (22%) survived for more than 20 years after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What were the significant prognostic factors identified in the study?\nAnswer: Significant prognostic factors included age, menstrual state, clinical stage, and the status of axillary nodes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What percentage of long-term survivors had pathologically affected axillary nodes?\nAnswer: 35% of the long-term survivors had pathologically affected axillary nodes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What was the relationship between tumor size and survival in the first five years?\nAnswer: Tumor size was a significant prognostic variable in predicting survival in the first five years after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: Did the study find a correlation between family history of breast cancer and long-term survival?\nAnswer: No, the study found no significant correlation between family history of breast cancer and long-term survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What was the average age of survivors compared to those who died within 20 years?\nAnswer: The average age of survivors was 47.7 years, while it was 53.2 years for those who died within 20 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What was concluded about the prognostic value of clinical stage after five years?\nAnswer: The prognostic value of clinical stage diminished significantly after five years, becoming of little value in predicting long-term survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: How many of the long-term survivors had grade 3 infiltrating ductal carcinomas?\nAnswer: 13 (25%) of the long-term survivors had grade 3 infiltrating ductal carcinomas.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "dfc55dbc5e8a489489cc3ae0e7b6a838",
            "source": "Which-patients-are-cured-of-breast-cancer",
            "main_category": "Which"
        },
        "page_content": "Question: What does the study suggest about late deaths from breast cancer?\nAnswer: The study suggests that many late deaths from breast cancer may be due to new tumors rather than a late manifestation of micrometastases from the original carcinoma.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What was the main objective of the KEYNOTE-119 trial?\nAnswer: The main objective of the KEYNOTE-119 trial was to compare pembrolizumab monotherapy against investigator-choice single-agent chemotherapy as a second-line or third-line treatment in patients with metastatic triple-negative breast cancer (mTNBC).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What were the primary and secondary endpoints of the KEYNOTE-119 trial?\nAnswer: The primary endpoint was overall survival (OS) analyzed in three groups based on PD-L1 tumor status. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), duration of response, and safety.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: How many participants were enrolled in the KEYNOTE-119 trial?\nAnswer: Out of 1098 participants assessed, 622 were randomized into the trial, with 312 assigned to the pembrolizumab group and 310 to the chemotherapy group.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What were the median overall survival results for the PD-L1 CPS \u226510 population?\nAnswer: For the PD-L1 CPS \u226510 population, the median overall survival was 12.7 months for pembrolizumab compared to 11.6 months for chemotherapy, with a hazard ratio of 0.78.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What safety profile was observed for pembrolizumab compared to chemotherapy?\nAnswer: Pembrolizumab was associated with fewer high-grade hematological adverse events compared to chemotherapy, particularly lower incidences of grade 3\u20134 neutropenia and leukopenia, while rates of serious adverse events were similar between the groups.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What conclusion was drawn regarding the effectiveness of pembrolizumab in the overall population?\nAnswer: Pembrolizumab monotherapy did not significantly improve overall survival compared to investigator-choice chemotherapy in the overall population or in the PD-L1 CPS \u22651 and \u226510 populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e57ded7ac7954a628e59929331589d4f",
            "source": "Winer-PembrolizumabVSChemo-2021",
            "main_category": "Winer"
        },
        "page_content": "Question: What potential future research direction was suggested by the trial findings?\nAnswer: The trial findings suggested that patients with high PD-L1 expression (CPS \u226520) might derive greater benefit from pembrolizumab, indicating the potential for PD-L1 enrichment to guide future treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What is the main focus of the study discussed in the document?\nAnswer: The study investigates whether de-glycosylating PD-L1 in tumor tissues improves its detection and better predicts responsiveness to atezolizumab in advanced breast cancer patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What is atezolizumab and its relevance in the study?\nAnswer: Atezolizumab (Tecentriq) is an anti-PD-L1 therapy approved for advanced triple-negative breast cancer (TNBC), and the study explores how de-glycosylated PD-L1 levels can serve as a biomarker for its effectiveness.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What were the methods used to analyze PD-L1 in tumor samples?\nAnswer: The study used immunohistochemical (IHC) staining with an anti-PD-L1 clone, applied a de-glycosylation step using PNGase F, and utilized four scoring systems to evaluate PD-L1 levels.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What were the key findings regarding de-glycosylated PD-L1 levels?\nAnswer: De-glycosylation significantly enhanced PD-L1 detection on tumor cell membranes, with higher levels correlating with better clinical responses to atezolizumab.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: How did the study assess the correlation between PD-L1 levels and clinical outcomes?\nAnswer: The study performed receiver operating characteristic (ROC) curve analyses to derive optimal cut-off points for predicting treatment response and evaluated correlations with progression-free survival (PFS) and treatment responses.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What conclusion did the authors draw about de-glycosylated PD-L1 as a biomarker?\nAnswer: The authors concluded that de-glycosylated PD-L1 levels correlate significantly with response to atezolizumab and may serve as a more reliable biomarker for patient selection compared to conventional IHC methods.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "feebca5baa764aecaade50d0599ea930",
            "source": "Yang-PDL1Tumor-2022",
            "main_category": "Yang"
        },
        "page_content": "Question: What is the significance of the study's findings for future research?\nAnswer: The findings suggest the need for further validation in larger, multi-institutional cohorts to optimize patient stratification for atezolizumab treatment.",
        "type": "Document"
    }
]